CD4	B-GP
+	O
T	O
Cells	O
Expressing	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
Contribute	O
to	O
HIV	B-OG
Persistence	O
during	O
ART	O

The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
RF	O
SGD	O
SRL	O
RPS	O
NC	O
.	O

Performed	O
the	O
experiments	O
:	O
RF	O
WB	O
MBL	O
GK	O
SD	O
MK	O
.	O

Analyzed	O
the	O
data	O
:	O
RF	O
WH	O
PB	O
MK	O
LE	O
RH	O
ES	O
FMH	O
.	O

Wrote	O
the	O
paper	O
:	O
RF	O
PB	O
SGD	O
SRL	O
RPS	O
NC	O
.	O

Exhaustion	O
of	O
Activated	O
CD8	B-GP
T	O
cells	O
Predicts	O
Disease	O
Progression	O
in	O
Primary	O
HIV	B-DS
-	I-DS
1	I-DS
Infection	I-DS

HIV	B-OG
persists	O
in	O
a	O
small	O
pool	O
of	O
latently	O
infected	O
cells	O
despite	O
antiretroviral	O
therapy	O
(	O
ART	O
).	O

Identifying	O
cellular	O
markers	O
expressed	O
at	O
the	O
surface	O
of	O
these	O
cells	O
may	O
lead	O
to	O
novel	O
therapeutic	O
strategies	O
to	O
reduce	O
the	O
size	O
of	O
the	O
HIV	B-OG
reservoir	O
.	O

We	O
hypothesized	O
that	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
immune	B-GP
checkpoint	I-GP
molecules	I-GP
would	O
be	O
enriched	O
in	O
HIV	B-OG
-	O
infected	O
cells	O
in	O
individuals	O
receiving	O
suppressive	O
ART	O
.	O

Expression	O
levels	O
of	O
7	O
immune	B-GP
checkpoint	I-GP
molecules	I-GP
(	O
PD	B-GP
-	I-GP
1	I-GP
,	O
CTLA	B-GP
-	I-GP
4	I-GP
,	O
LAG	B-GP
-	I-GP
3	I-GP
,	O
TIGIT	B-GP
,	O
TIM	B-GP
-	I-GP
3	I-GP
,	O
CD160	B-GP
and	O
2B4	B-GP
)	O
as	O
well	O
as	O
4	O
markers	O
of	O
HIV	B-OG
persistence	O
(	O
integrated	O
and	O
total	O
HIV	B-OG
DNA	O
,	O
2	O
-	O
LTR	O
circles	O
and	O
cell	O
-	O
associated	O
unspliced	O
HIV	B-OG
RNA	O
)	O
were	O
measured	O
in	O
PBMCs	O
from	O
48	O
virally	O
suppressed	O
individuals	O
.	O

Using	O
negative	O
binomial	O
regression	O
models	O
,	O
we	O
identified	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
as	O
immune	B-GP
checkpoint	I-GP
molecules	I-GP
positively	O
associated	O
with	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
.	O

The	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
co	O
-	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
independently	O
predicted	O
the	O
frequency	O
of	O
cells	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
.	O

Quantification	O
of	O
HIV	B-OG
genomes	O
in	O
highly	O
purified	O
cell	O
subsets	O
from	O
blood	O
further	O
revealed	O
that	O
expressions	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
were	O
associated	O
with	O
HIV	B-OG
-	O
infected	O
cells	O
in	O
distinct	O
memory	O
CD4	B-GP
+	O
T	O
cell	O
subsets	O
.	O

CD4	B-GP
+	O
T	O
cells	O
co	O
-	O
expressing	O
the	O
three	O
markers	O
were	O
highly	O
enriched	O
for	O
integrated	O
viral	O
genomes	O
(	O
median	O
of	O
8	O
.	O
2	O
fold	O
compared	O
to	O
total	O
CD4	B-GP
+	O
T	O
cells	O
).	O

Importantly	O
,	O
most	O
cells	O
carrying	O
inducible	O
HIV	B-OG
genomes	O
expressed	O
at	O
least	O
one	O
of	O
these	O
markers	O
(	O
median	O
contribution	O
of	O
cells	O
expressing	O
LAG	B-GP
-	I-GP
3	I-GP
,	O
PD	B-GP
-	I-GP
1	I-GP
or	O
TIGIT	B-GP
to	O
the	O
inducible	O
reservoir	O
=	O
76	O
%).	O

Our	O
data	O
provide	O
evidence	O
that	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
alone	O
or	O
in	O
combination	O
are	O
enriched	O
for	O
persistent	O
HIV	B-OG
during	O
ART	O
and	O
suggest	O
that	O
immune	O
checkpoint	O
blockers	O
directed	O
against	O
these	O
receptors	O
may	O
represent	O
valuable	O
tools	O
to	O
target	O
latently	O
infected	O
cells	O
in	O
virally	O
suppressed	O
individuals	O
.	O

Author	O
Summary	O

The	O
persistence	O
of	O
HIV	B-OG
in	O
a	O
small	O
pool	O
of	O
long	O
-	O
lived	O
latently	O
infected	O
resting	O
CD4	B-GP
+	O
T	O
cells	O
is	O
a	O
major	O
barrier	O
to	O
viral	O
eradication	O
.	O

Identifying	O
cellular	O
markers	O
that	O
are	O
preferentially	O
expressed	O
at	O
the	O
surface	O
of	O
latently	O
infected	O
cells	O
may	O
lead	O
to	O
novel	O
therapeutic	O
strategies	O
to	O
cure	O
HIV	B-DS
infection	I-DS
.	O

We	O
identified	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
as	O
markers	O
preferentially	O
expressed	O
at	O
the	O
surface	O
of	O
infected	O
cells	O
in	O
individuals	O
receiving	O
ART	O
.	O

CD4	B-GP
+	O
T	O
cells	O
co	O
-	O
expressing	O
these	O
markers	O
were	O
highly	O
enriched	O
for	O
cells	O
carrying	O
HIV	B-OG
.	O

Our	O
results	O
suggest	O
that	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
may	O
represent	O
new	O
molecular	O
targets	O
to	O
interfere	O
with	O
HIV	B-OG
persistence	O
during	O
ART	O
.	O

Introduction	O

Although	O
antiretroviral	O
therapy	O
(	O
ART	O
)	O
is	O
highly	O
effective	O
at	O
suppressing	O
HIV	B-OG
replication	O
,	O
viral	O
reservoirs	O
persist	O
despite	O
treatment	O
and	O
lead	O
to	O
rapid	O
viral	O
rebound	O
when	O
ART	O
is	O
interrupted	O
[	O
1	O
–	O
4	O
].	O

A	O
major	O
step	O
to	O
achieve	O
natural	O
control	O
of	O
HIV	B-OG
replication	O
after	O
ART	O
cessation	O
would	O
be	O
to	O
eliminate	O
,	O
or	O
at	O
least	O
reduce	O
,	O
the	O
number	O
of	O
long	O
-	O
lived	O
infected	O
cells	O
from	O
which	O
HIV	B-OG
reignite	O
infection	B-DS
.	O

The	O
characterization	O
of	O
cell	O
surface	O
markers	O
that	O
could	O
identify	O
HIV	B-OG
-	O
infected	O
cells	O
persisting	O
during	O
ART	O
is	O
a	O
research	O
priority	O
towards	O
an	O
HIV	B-OG
cure	O
[	O
5	O
]	O
as	O
it	O
could	O
lead	O
to	O
the	O
development	O
of	O
novel	O
eradication	O
strategies	O
.	O

Several	O
subsets	O
of	O
CD4	B-GP
+	O
T	O
cells	O
harbor	O
replication	O
-	O
competent	O
HIV	B-OG
during	O
ART	O
.	O

These	O
CD4	B-GP
+	O
T	O
cells	O
are	O
usually	O
defined	O
on	O
the	O
basis	O
of	O
their	O
differentiation	O
stage	O
[	O
6	O
–	O
8	O
],	O
functionality	O
or	O
homing	O
potential	O
[	O
9	O
,	O
10	O
].	O

Central	O
memory	O
(	O
TCM	O
)	O
and	O
transitional	O
memory	O
(	O
TTM	O
)	O
CD4	B-GP
+	O
T	O
cells	O
were	O
identified	O
as	O
the	O
major	O
cellular	O
reservoirs	O
for	O
HIV	B-OG
during	O
ART	O
[	O
6	O
].	O

More	O
recently	O
,	O
a	O
less	O
differentiated	O
subset	O
of	O
long	O
-	O
lived	O
cells	O
with	O
high	O
self	O
-	O
renewal	O
capacity	O
,	O
the	O
stem	O
-	O
cell	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
(	O
TSCM	O
),	O
has	O
been	O
identified	O
as	O
a	O
main	O
contributor	O
to	O
long	O
-	O
term	O
HIV	B-OG
persistence	O
[	O
7	O
,	O
8	O
].	O

The	O
functional	O
and	O
homing	O
capacities	O
of	O
CD4	B-GP
+	O
T	O
cells	O
also	O
dictate	O
their	O
capacity	O
to	O
serve	O
as	O
persistent	O
reservoirs	O
for	O
HIV	B-OG
:	O
Th17	O
and	O
Th1	O
/	O
Th17	O
CD4	B-GP
+	O
T	O
cells	O
as	O
well	O
as	O
cells	O
expressing	O
CCR6	B-GP
and	O
CXCR3	B-GP
show	O
increasing	O
contribution	O
to	O
the	O
viral	O
reservoir	O
with	O
duration	O
of	O
ART	O
[	O
11	O
,	O
12	O
].	O

Immune	B-GP
checkpoint	I-GP
molecules	I-GP
(	O
ICs	B-GP
)	O
are	O
co	B-GP
-	I-GP
inhibitory	I-GP
receptors	I-GP
which	O
down	O
-	O
modulate	O
immune	O
responses	O
to	O
prevent	O
hyper	O
-	O
immune	O
activation	O
,	O
minimize	O
collateral	O
damage	O
,	O
and	O
maintain	O
peripheral	O
self	O
-	O
tolerance	O
[	O
13	O
].	O

ICs	B-GP
are	O
up	O
regulated	O
upon	O
T	O
-	O
cell	O
activation	O
and	O
constrain	O
the	O
effector	O
response	O
through	O
feedback	O
inhibition	O
.	O

Overexpression	O
of	O
these	O
molecules	O
is	O
associated	O
with	O
T	O
-	O
cell	O
exhaustion	O
and	O
dysfunction	O
in	O
cancer	B-DS
and	O
chronic	B-DS
viral	I-DS
infections	I-DS
,	O
including	O
HIV	B-OG
[	O
14	O
–	O
17	O
].	O

We	O
hypothesized	O
that	O
ICs	B-GP
,	O
through	O
their	O
ability	O
to	O
inhibit	O
T	O
-	O
cell	O
activation	O
,	O
will	O
favour	O
HIV	B-OG
latency	O
during	O
ART	O
,	O
and	O
that	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
ICs	B-GP
would	O
be	O
enriched	O
for	O
persistent	O
HIV	B-OG
in	O
individuals	O
receiving	O
ART	O
.	O

We	O
focused	O
our	O
analysis	O
on	O
7	O
ICs	B-GP
,	O
namely	O
PD	B-GP
-	I-GP
1	I-GP
(	O
programmed	B-GP
cell	I-GP
death	I-GP
-	I-GP
1	I-GP
),	O
CTLA	B-GP
-	I-GP
4	I-GP
(	O
cytotoxic	B-GP
T	I-GP
-	I-GP
lymphocyte	I-GP
-	I-GP
associated	I-GP
protein	I-GP
4	I-GP
),	O
LAG	B-GP
-	I-GP
3	I-GP
(	O
lymphocyte	B-GP
activation	I-GP
gene	I-GP
3	I-GP
),	O
TIGIT	B-GP
(	O
T	B-GP
-	I-GP
cell	I-GP
immunoglobulin	I-GP
and	I-GP
ITIM	I-GP
domain	I-GP
),	O
TIM	B-GP
-	I-GP
3	I-GP
(	O
T	B-GP
cell	I-GP
immunoglobulin	I-GP
and	I-GP
mucin	I-GP
3	I-GP
),	O
CD160	B-GP
and	O
2B4	B-GP
(	O
CD244	B-GP
).	O

PD	B-GP
-	I-GP
1	I-GP
,	O
a	O
member	O
of	O
the	O
B7	B-GP
-	O
CD28	B-GP
superfamily	O
,	O
enforces	O
an	O
inhibitory	O
program	O
that	O
blocks	O
further	O
TCR	B-GP
-	O
induced	O
T	O
-	O
cell	O
proliferation	O
and	O
cytokine	B-GP
production	O
[	O
18	O
,	O
19	O
].	O

In	O
HIV	B-DS
infection	I-DS
,	O
high	O
levels	O
of	O
PD	B-GP
-	I-GP
1	I-GP
are	O
associated	O
with	O
T	O
cell	O
exhaustion	O
[	O
14	O
–	O
16	O
,	O
20	O
]	O
and	O
incomplete	O
immunological	O
response	O
to	O
ART	O
[	O
21	O
].	O

CTLA	B-GP
-	I-GP
4	I-GP
,	O
a	O
CD28	B-GP
homolog	I-GP
,	O
regulates	O
the	O
amplitude	O
of	O
T	O
-	O
cell	O
activation	O
by	O
both	O
outcompeting	O
CD28	B-GP
in	O
binding	O
CD80	B-GP
and	O
CD86	B-GP
,	O
as	O
well	O
as	O
actively	O
delivering	O
inhibitory	O
signals	O
to	O
T	O
cells	O
[	O
13	O
].	O

TIGIT	B-GP
,	O
which	O
also	O
belongs	O
to	O
the	O
B7	B-GP
/	O
CD28	B-GP
superfamily	O
,	O
acts	O
as	O
a	O
co	O
-	O
inhibitory	O
molecule	O
by	O
directly	O
down	O
regulating	O
proliferation	O
of	O
human	B-OG
T	O
cells	O
[	O
22	O
],	O
but	O
also	O
by	O
modulating	O
cytokine	B-GP
secretion	O
of	O
DCs	O
,	O
decreasing	O
IL	B-GP
-	I-GP
12	I-GP
and	O
enhancing	O
IL	B-GP
-	I-GP
10	I-GP
productions	O
[	O
23	O
].	O

TIGIT	B-GP
has	O
been	O
recently	O
associated	O
with	O
CD8	B-GP
+	O
T	O
-	O
cell	O
dysfunction	O
during	O
HIV	B-DS
infection	I-DS
[	O
24	O
].	O

The	O
expression	O
of	O
2B4	B-GP
(	O
CD244	B-GP
),	O
a	O
member	O
of	O
the	O
signalling	B-GP
lymphocyte	I-GP
activation	I-GP
molecule	I-GP
(	O
SLAM	B-GP
)	O
is	O
also	O
modulated	O
on	O
T	O
cells	O
during	O
HIV	B-DS
infection	I-DS
[	O
17	O
,	O
25	O
].	O

LAG	B-GP
-	I-GP
3	I-GP
,	O
a	O
member	O
of	O
the	O
immunoglobulin	B-GP
superfamily	O
,	O
is	O
structurally	O
highly	O
homologous	O
to	O
the	O
CD4	B-GP
receptor	I-GP
and	O
share	O
MHC	B-GP
-	I-GP
II	I-GP
as	O
a	O
ligand	O
[	O
26	O
].	O

Its	O
expression	O
on	O
T	O
regulatory	O
cells	O
plays	O
a	O
role	O
in	O
the	O
modulation	O
of	O
T	O
cell	O
homeostasis	O
and	O
effector	O
T	O
cell	O
responses	O
[	O
27	O
,	O
28	O
].	O

TIM	B-GP
-	I-GP
3	I-GP
is	O
also	O
an	O
immunoglobulin	B-GP
superfamily	O
member	O
and	O
its	O
expression	O
is	O
increased	O
on	O
HIV	B-OG
-	O
specific	O
CD8	B-GP
+	O
and	O
CD4	B-GP
+	O
T	O
cells	O
[	O
29	O
,	O
30	O
].	O

Finally	O
,	O
CD160	B-GP
,	O
through	O
its	O
binding	O
to	O
its	O
ligand	O
Herpes	B-GP
Virus	I-GP
Entry	I-GP
Mediator	I-GP
(	O
HVEM	B-GP
),	O
an	O
atypical	O
member	O
of	O
TNF	B-GP
-	I-GP
receptor	I-GP
superfamily	O
,	O
delivers	O
a	O
co	O
-	O
inhibitory	O
signalling	O
to	O
CD4	B-GP
+	O
T	O
cells	O
or	O
CD8	B-GP
+	O
T	O
cells	O
dampening	O
their	O
activation	O
in	O
HIV	B-OG
-	O
infected	O
individuals	O
[	O
31	O
,	O
32	O
].	O

To	O
assess	O
the	O
relationship	O
between	O
the	O
expression	O
of	O
these	O
ICs	B-GP
and	O
HIV	B-OG
persistence	O
,	O
we	O
analysed	O
the	O
association	O
between	O
their	O
levels	O
of	O
expression	O
on	O
CD4	B-GP
+	O
T	O
cells	O
and	O
the	O
size	O
of	O
the	O
HIV	B-OG
reservoir	O
in	O
individuals	O
receiving	O
ART	O
for	O
at	O
least	O
3	O
years	O
.	O

Materials	O
and	O
Methods	O

Study	O
participants	O

Forty	O
-	O
eight	O
HIV	B-OG
-	O
infected	O
participants	O
receiving	O
suppressive	O
ART	O
were	O
recruited	O
at	O
the	O
University	O
of	O
California	O
San	O
Francisco	O
(	O
UCSF	O
)	O
for	O
this	O
cross	O
-	O
sectional	O
study	O
.	O

Participants	O
were	O
receiving	O
ART	O
for	O
>	O
3	O
years	O
,	O
had	O
CD4	B-GP
+	O
T	O
-	O
cell	O
count	O
>	O
350	O
cells	O
/	O
μl	O
and	O
HIV	B-OG
RNA	O
<	O
40	O
copies	O
/	O
mL	O
as	O
measured	O
by	O
the	O
Abbott	O
real	O
time	O
HIV	B-OG
-	I-OG
1	I-OG
PCR	O
for	O
at	O
least	O
3	O
years	O
.	O

Whole	O
blood	O
(	O
50mL	O
)	O
was	O
collected	O
by	O
regular	O
blood	O
draw	O
.	O

For	O
cell	O
sorting	O
experiments	O
,	O
27	O
HIV	B-OG
-	O
infected	O
individuals	O
were	O
enrolled	O
at	O
UCSF	O
and	O
at	O
VGTIFL	O
and	O
underwent	O
leukapheresis	O
.	O

Ethics	O
statement	O

All	O
subjects	O
signed	O
informed	O
consent	O
forms	O
approved	O
by	O
the	O
UCSF	O
and	O
Martin	O
Memorial	O
Health	O
Systems	O
review	O
boards	O
(	O
IRB	O
#	O
10	O
–	O
1320	O
,	O
Ref	O
#	O
068192	O
and	O
FWA	O
#	O
00004139	O
,	O
respectively	O
).	O

Immunophenotyping	O

PBMCs	O
were	O
isolated	O
from	O
peripheral	O
blood	O
and	O
leukapheresis	O
using	O
previously	O
described	O
methods	O
[	O
6	O
,	O
33	O
].	O

Cryopreserved	O
PBMCs	O
were	O
thawed	O
,	O
washed	O
and	O
stained	O
for	O
phenotyping	O
or	O
cell	O
sorting	O
.	O

Two	O
antibody	B-GP
panels	O
were	O
used	O
to	O
measure	O
the	O
expression	O
of	O
IC	O
in	O
subsets	O
of	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
.	O

The	O
same	O
antibody	B-GP
backbone	O
was	O
used	O
in	O
the	O
two	O
panels	O
:	O
CD3	B-GP
-	O
Alexa700	O
(	O
clone	O
UCHT1	O
,	O
BD	O
#	O
557943	O
),	O
CD4	B-GP
-	O
QDot605	O
(	O
clone	O
S3	O
.	O
5	O
,	O
Invitrogen	O
#	O
Q10008	O
),	O
CD8	B-GP
-	O
PB	O
(	O
clone	O
RPA	O
-	O
T8	O
,	O
BD	O
#	O
558207	O
),	O
CD14	B-GP
-	O
V500	O
(	O
clone	O
M5E2	O
,	O
BD	O
#	O
561391	O
),	O
CD19	B-GP
-	O
AmCyan	O
(	O
clone	O
SJ25C1	O
,	O
BD	O
#	O
339190	O
),	O
LIVE	O
/	O
DEAD	O
Aqua	O
marker	O
(	O
Invitrogen	O
#	O
L34957	O
),	O
CD45RA	B-GP
-	O
APC	O
-	O
H7	O
(	O
clone	O
HI100	O
,	O
BD	O
#	O
560674	O
),	O
CD27	B-GP
-	O
BV650	O
(	O
clone	O
O323	O
,	O
Biolegend	O
#	O
302828	O
)	O
and	O
CCR7	B-GP
-	O
PE	B-GP
-	O
Cy7	O
(	O
clone	O
3D12	O
,	O
BD	O
#	O
557648	O
).	O

The	O
following	O
antibodies	B-GP
were	O
added	O
to	O
this	O
backbone	O
:	O
PD	B-GP
-	I-GP
1	I-GP
-	O
AF647	O
(	O
clone	O
EH12	O
.	O
1	O
,	O
BD	O
#	O
560838	O
),	O
CTLA	B-GP
-	I-GP
4	I-GP
-	O
PE	B-GP
(	O
clone	O
BNI3	O
,	O
BD	O
#	O
555853	O
),	O
LAG	B-GP
-	I-GP
3	I-GP
-	O
FITC	O
(	O
R	O
&	O
D	O
#	O
FAB2319F	O
),	O
TIGIT	B-GP
-	O
PerCP	O
-	O
eF710	O
(	O
clone	O
MBSA43	O
,	O
eBioscience	O
#	O
46	O
-	O
9500	O
-	O
41	O
),	O
TIM	B-GP
-	I-GP
3	I-GP
-	O
PE	B-GP
(	O
clone	O
F38	O
-	O
2E2	O
,	O
Biolegend	O
#	O
345006	O
),	O
CD160	B-GP
-	O
AF488	O
(	O
clone	O
By55	O
,	O
eBioscience	O
#	O
53	O
–	O
1609	O
),	O
2B4	B-GP
-	O
PerCP	O
-	O
Cy5	O
.	O
5	O
(	O
clone	O
C1	O
.	O
7	O
,	O
Biolegend	O
#	O
329515	O
).	O

For	O
expression	O
of	O
all	O
ICs	B-GP
,	O
gates	O
were	O
defined	O
using	O
fluorescence	O
minus	O
one	O
controls	O
.	O

CD4	B-GP
+	O
T	O
-	O
cell	O
subsets	O
were	O
identified	O
by	O
CD27	B-GP
,	O
CD45RA	B-GP
,	O
and	O
CCR7	B-GP
expression	O
on	O
CD4	B-GP
+	O
T	O
cells	O
after	O
exclusion	O
of	O
dump	O
positive	O
cells	O
(	O
LIVE	O
/	O
DEAD	O
,	O
CD14	B-GP
and	O
CD19	B-GP
).	O

ICs	B-GP
were	O
measured	O
in	O
gated	O
CD4	B-GP
+	O
T	O
-	O
cell	O
subsets	O
including	O
naïve	O
CD4	B-GP
+	O
T	O
cells	O
(	O
CD3	B-GP
+	O
CD8	B-GP
-	O
CD4	B-GP
+	O
CD45RA	B-GP
+	O
CCR7	B-GP
+	O
CD27	B-GP
+),	O
central	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
(	O
CD3	B-GP
+	O
CD8	B-GP
-	O
CD4	B-GP
+	O
CD45RA	B-GP
-	O
CCR7	B-GP
+	O
CD27	B-GP
+),	O
transitional	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
(	O
CD3	B-GP
+	O
CD8	B-GP
-	O
CD4	B-GP
+	O
CD45RA	B-GP
-	O
CCR7	B-GP
-	O
CD27	B-GP
+),	O
effector	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
(	O
CD3	B-GP
+	O
CD8	B-GP
-	O
CD4	B-GP
+	O
CD45RA	B-GP
-	O
CCR7	B-GP
-	O
CD27	B-GP
-)	O
and	O
terminally	O
differentiated	O
CD4	B-GP
+	O
T	O
cells	O
(	O
CD3	B-GP
+	O
CD8	B-GP
-	O
CD4	B-GP
+	O
CD45RA	B-GP
+	O
CCR7	B-GP
-	O
CD27	B-GP
-).	O

Data	O
was	O
acquired	O
on	O
a	O
BD	O
LSR	O
II	O
flow	O
cytometer	O
using	O
the	O
FACSDiva	O
software	O
(	O
Becton	O
Dickinson	O
)	O
and	O
analysed	O
using	O
Flow	O
Jo	O
version	O
9	O
(	O
Treestar	O
).	O

Cell	O
sorting	O

Central	O
,	O
transitional	O
and	O
effector	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
were	O
sorted	O
based	O
on	O
their	O
expression	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
or	O
LAG	B-GP
-	I-GP
3	I-GP
.	O

The	O
antibodies	B-GP
used	O
for	O
sorting	O
were	O
similar	O
than	O
those	O
used	O
for	O
phenotyping	O
with	O
the	O
exception	O
of	O
CD27	B-GP
-	O
QDot655	O
(	O
clone	O
CLB	O
-	O
27	O
/	O
1	O
,	O
Invitrogen	O
#	O
Q10066	O
).	O

In	O
a	O
second	O
set	O
of	O
experiments	O
,	O
total	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
(	O
CD3	B-GP
+	O
CD4	B-GP
+	O
CD45RA	B-GP
-)	O
were	O
sorted	O
based	O
on	O
their	O
expression	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
.	O

Sorted	O
cells	O
were	O
collected	O
using	O
an	O
ARIA	O
FACS	O
sorter	O
(	O
Becton	O
Dickinson	O
).	O

Isolation	O
of	O
total	O
CD4	B-GP
+	O
T	O
cells	O

Total	O
CD4	B-GP
+	O
T	O
cells	O
were	O
isolated	O
from	O
cryopreserved	O
PBMCs	O
using	O
magnetic	O
depletion	O
as	O
per	O
the	O
manufacturer	O
’	O
s	O
protocol	O
(	O
Stem	O
Cell	O
Technologies	O
,	O
Vancouver	O
,	O
Canada	O
).	O

Quantification	O
of	O
integrated	O
,	O
total	O
and	O
2	O
-	O
LTR	O
circles	O
HIV	B-OG
DNA	O
,	O
cell	O
associated	O
unspliced	O
HIV	B-OG
RNA	O
and	O
Tat	O
/	O
rev	O
inducible	O
multiply	O
spliced	O
HIV	B-OG
RNA	O

Total	O
CD4	B-GP
+	O
T	O
cells	O
or	O
sorted	O
CD4	B-GP
+	O
T	O
cell	O
subsets	O
were	O
used	O
to	O
measure	O
the	O
frequency	O
of	O
cells	O
harboring	O
HIV	B-OG
DNA	O
(	O
total	O
,	O
integrated	O
and	O
2	O
-	O
LTR	O
circles	O
)	O
by	O
real	O
time	O
nested	O
PCR	O
as	O
previously	O
described	O
[	O
34	O
]	O
(	O
S1A	O
Text	O
).	O

The	O
CA	O
-	O
US	O
RNA	O
was	O
measured	O
by	O
real	O
time	O
nested	O
PCR	O
as	O
previously	O
described	O
[	O
35	O
].	O

The	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
with	O
inducible	O
multiply	O
spliced	O
HIV	B-OG
RNA	O
was	O
determined	O
using	O
Tat	O
/	O
rev	O
inducible	O
limiting	O
dilution	O
assay	O
(	O
TILDA	O
)	O
[	O
36	O
].	O

Statistical	O
analysis	O

Data	O
distributions	O
were	O
assessed	O
through	O
descriptive	O
statistics	O
and	O
scatter	O
plots	O
.	O

Negative	O
binomial	O
regression	O
models	O
were	O
run	O
for	O
each	O
set	O
of	O
comparisons	O
with	O
the	O
percentage	O
of	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
ICs	B-GP
being	O
the	O
predictor	O
and	O
the	O
measure	O
of	O
HIV	B-OG
persistence	O
the	O
outcome	O
.	O

We	O
chose	O
this	O
approach	O
for	O
reasons	O
described	O
previously	O
[	O
12	O
,	O
35	O
],	O
and	O
for	O
consistency	O
with	O
those	O
previous	O
publications	O
(	O
S1B	O
Text	O
).	O

The	O
approach	O
allowed	O
us	O
to	O
fit	O
models	O
adjusting	O
for	O
the	O
effects	O
of	O
absolute	O
current	O
or	O
nadir	O
CD4	B-GP
+	O
T	O
-	O
cell	O
,	O
which	O
were	O
examined	O
for	O
all	O
combinations	O
of	O
IC	O
predictors	O
and	O
HIV	B-OG
persistence	O
outcome	O
measures	O
.	O

In	O
addition	O
,	O
the	O
negative	O
binomial	O
regression	O
models	O
take	O
into	O
account	O
that	O
copies	O
/	O
input	O
is	O
measured	O
with	O
less	O
precision	O
when	O
the	O
number	O
of	O
copies	O
is	O
lower	O
and	O
when	O
the	O
amount	O
of	O
input	O
is	O
lower	O
.	O

The	O
methods	O
also	O
permit	O
proper	O
quantitative	O
use	O
of	O
instances	O
where	O
zero	O
copies	O
were	O
present	O
in	O
the	O
specimen	O
assayed	O
,	O
without	O
a	O
need	O
for	O
ad	O
hoc	O
modifications	O
to	O
permit	O
taking	O
logarithms	O
.	O

We	O
did	O
not	O
evaluate	O
the	O
results	O
of	O
alternative	O
analysis	O
methods	O
and	O
did	O
not	O
choose	O
the	O
methods	O
post	O
-	O
hoc	O
based	O
on	O
the	O
results	O
that	O
they	O
produced	O
.	O

Analyses	O
were	O
run	O
in	O
Stata	O
version	O
13	O
.	O
1	O
(	O
Stata	O
Corp	O
,	O
College	O
Station	O
,	O
TX	O
).	O

For	O
TILDA	O
results	O
analysis	O
,	O
we	O
estimated	O
the	O
within	O
-	O
person	O
fold	O
difference	O
in	O
TILDA	O
between	O
the	O
2	O
cell	O
subsets	O
analyzed	O
(	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
any	O
versus	O
none	O
of	O
the	O
ICs	B-GP
)	O
by	O
fitting	O
a	O
maximum	O
likelihood	O
model	O
to	O
the	O
raw	O
data	O
on	O
numbers	O
of	O
positive	O
and	O
negative	O
wells	O
at	O
each	O
dilution	O
(	O
S1C	O
Text	O
).	O

Results	O

PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
are	O
associated	O
with	O
markers	O
of	O
HIV	B-OG
persistence	O
during	O
ART	O

To	O
determine	O
the	O
relationship	O
between	O
ICs	B-GP
and	O
HIV	B-OG
persistence	O
,	O
48	O
HIV	B-OG
-	O
infected	O
participants	O
on	O
suppressive	O
ART	O
for	O
a	O
median	O
time	O
(	O
IQR	O
)	O
of	O
8	O
.	O
5	O
years	O
(	O
5	O
.	O
0	O
–	O
12	O
.	O
4	O
)	O
and	O
a	O
median	O
CD4	B-GP
+	O
T	O
-	O
cell	O
count	O
(	O
IQR	O
)	O
of	O
684	O
cells	O
/	O
μL	O
(	O
533	O
–	O
858	O
)	O
were	O
recruited	O
(	O
Table	O
1	O
).	O

The	O
expressions	O
of	O
7	O
ICs	B-GP
on	O
CD4	B-GP
+	O
T	O
cells	O
(	O
PD	B-GP
-	I-GP
1	I-GP
,	O
CTLA	B-GP
-	I-GP
4	I-GP
,	O
LAG	B-GP
-	I-GP
3	I-GP
,	O
TIGIT	B-GP
,	O
TIM	B-GP
-	I-GP
3	I-GP
,	O
CD160	B-GP
and	O
2B4	B-GP
)	O
were	O
measured	O
by	O
multiparametric	O
flow	O
cytometry	O
(	O
S1	O
Fig	O
).	O

The	O
frequencies	O
of	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
these	O
ICs	B-GP
were	O
variable	O
(	O
median	O
(	O
IQR	O
)	O
of	O
16	O
.	O
7	O
%	O
(	O
13	O
.	O
2	O
–	O
22	O
.	O
7	O
),	O
12	O
.	O
2	O
%	O
(	O
8	O
.	O
8	O
–	O
16	O
.	O
4	O
),	O
12	O
.	O
0	O
%	O
(	O
8	O
.	O
9	O
–	O
16	O
.	O
1	O
),	O
9	O
.	O
5	O
%	O
(	O
3	O
.	O
5	O
–	O
18	O
.	O
5	O
),	O
1	O
.	O
1	O
%	O
(	O
0	O
.	O
8	O
–	O
2	O
.	O
5	O
),	O
0	O
.	O
8	O
%	O
(	O
0	O
.	O
6	O
–	O
1	O
.	O
5	O
)	O
and	O
0	O
.	O
7	O
%	O
(	O
0	O
.	O
6	O
–	O
1	O
.	O
0	O
)	O
for	O
TIGIT	B-GP
,	O
PD	B-GP
-	I-GP
1	I-GP
,	O
LAG	B-GP
-	I-GP
3	I-GP
,	O
2B4	B-GP
,	O
CD160	B-GP
,	O
TIM	B-GP
-	I-GP
3	I-GP
and	O
CTLA	B-GP
-	I-GP
4	I-GP
respectively	O
)	O
(	O
Fig	O
1A	O
).	O

Clinical	O
demographics	O
of	O
the	O
cohorts	O
.	O

Characteristics	O

Cohort	O
1	O
(	O
N	O
=	O
48	O
)	O

Cohort	O
2	O
(	O
N	O
=	O
31	O
)	O

Gender	O
,	O
n	O
(%)	O

Male	O

46	O
(	O
96	O
%)	O

29	O
(	O
94	O
%)	O

Female	O

1	O
(	O
2	O
%)	O

2	O
(	O
6	O
%)	O

Transgender	O

1	O
(	O
2	O
%)	O

0	O
(	O
0	O
%)	O

Age	O
,	O
years	O
median	O
(	O
IQR	O
)	O

57	O
(	O
50	O
–	O
62	O
)	O

50	O
(	O
50	O
–	O
62	O
)	O

Viral	O
load	O
,	O
cop	O
/	O
mL	O

<	O
50	O

<	O
50	O

Nadir	O
CD4	B-GP
+	O
T	O
-	O
cell	O
count	O
,	O
cells	O
/	O
μl	O
median	O
(	O
IQR	O
)	O

197	O
(	O
110	O
–	O
285	O
)	O
a	O

42	O
(	O
14	O
–	O
179	O
)	O
b	O

Current	O
CD4	B-GP
+	O
T	O
-	O
cell	O
count	O
,	O
cells	O
/	O
μl	O
median	O
(	O
IQR	O
)	O

684	O
(	O
530	O
–	O
862	O
)	O

526	O
(	O
420	O
–	O
702	O
)	O

Current	O
CD8	B-GP
+	O
T	O
-	O
cell	O
count	O
,	O
cells	O
/	O
μl	O
median	O
(	O
IQR	O
)	O

914	O
(	O
639	O
–	O
1091	O
)	O

830	O
(	O
617	O
–	O
1135	O
)	O

CD4	B-GP
/	O
CD8	B-GP
ratio	O
median	O
(	O
IQR	O
)	O

0	O
.	O
77	O
(	O
0	O
.	O
57	O
–	O
1	O
.	O
17	O
)	O

0	O
.	O
64	O
(	O
0	O
.	O
40	O
–	O
0	O
.	O
91	O
)	O

ART	O
,	O
years	O
median	O
(	O
IQR	O
)	O

8	O
.	O
5	O
(	O
5	O
.	O
0	O
–	O
12	O
.	O
4	O
)	O

8	O
.	O
8	O
(	O
6	O
.	O
2	O
–	O
12	O
.	O
6	O
)	O
c	O

Data	O
only	O
available	O
for	O
(	O
a	O
)	O
N	O
=	O
45	O
,	O
(	O
b	O
)	O
N	O
=	O
27	O
,	O
(	O
c	O
)	O
N	O
=	O
24	O

PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
are	O
associated	O
with	O
virological	O
markers	O
of	O
HIV	B-OG
persistence	O
during	O
ART	O
.	O

(	O
A	O
)	O
Expression	O
of	O
7	O
ICs	B-GP
on	O
CD4	B-GP
+	O
T	O
cells	O
in	O
individuals	O
receiving	O
suppressive	O
ART	O
(	O
n	O
=	O
48	O
).	O

Data	O
is	O
represented	O
as	O
percentage	O
of	O
CD4	B-GP
+	O
T	O
cells	O
and	O
horizontal	O
bars	O
indicate	O
median	O
values	O
with	O
interquartile	O
ranges	O
.	O

(	O
B	O
)	O
Size	O
of	O
the	O
HIV	B-OG
reservoir	O
measured	O
by	O
integrated	O
HIV	B-OG
DNA	O
,	O
total	O
HIV	B-OG
DNA	O
,	O
2	O
-	O
LTR	O
circles	O
represented	O
as	O
copies	O
per	O
million	O
CD4	B-GP
+	O
T	O
cells	O
and	O
cell	O
-	O
associated	O
US	O
HIV	B-OG
RNA	O
represented	O
as	O
copies	O
per	O
million	O
copies	O
of	O
18S	O
.	O

Horizontal	O
bars	O
indicate	O
median	O
values	O
with	O
interquartile	O
ranges	O
and	O
open	O
circles	O
represent	O
the	O
limit	O
of	O
detection	O
in	O
the	O
negative	O
samples	O
(	O
based	O
on	O
cell	O
input	O
).	O

(	O
C	O
),	O
(	O
D	O
),	O
(	O
E	O
)	O
Associations	O
between	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
and	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
,	O
respectively	O
.	O

P	O
values	O
were	O
obtained	O
from	O
negative	O
binomial	O
regression	O
analysis	O
.	O

Effect	O
sizes	O
for	O
the	O
associations	O
are	O
as	O
follows	O
:	O
(	O
C	O
)	O
A	O
2	O
-	O
fold	O
increase	O
in	O
the	O
percentage	O
of	O
PD	B-GP
-	I-GP
1	I-GP
+	O
CD4	B-GP
+	O
T	O
cell	O
was	O
associated	O
with	O
1	O
.	O
43	O
-	O
fold	O
increase	O
in	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cell	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
,	O
(	O
D	O
)	O
a	O
2	O
-	O
fold	O
higher	O
percentage	O
of	O
TIGIT	B-GP
+	O
CD4	B-GP
+	O
T	O
cell	O
was	O
associated	O
with	O
1	O
.	O
91	O
-	O
fold	O
higher	O
integrated	O
HIV	B-OG
DNA	O
and	O
(	O
E	O
)	O
a	O
2	O
-	O
fold	O
higher	O
percentage	O
of	O
LAG	B-GP
-	I-GP
3	I-GP
+	O
CD4	B-GP
+	O
T	O
cell	O
was	O
associated	O
with	O
1	O
.	O
62	O
-	O
fold	O
higher	O
integrated	O
HIV	B-OG
DNA	O
.	O

Open	O
circles	O
represent	O
the	O
limit	O
of	O
detection	O
in	O
the	O
negative	O
samples	O
(	O
based	O
on	O
cell	O
input	O
).	O

The	O
size	O
of	O
the	O
HIV	B-OG
reservoir	O
was	O
determined	O
by	O
measuring	O
the	O
frequencies	O
of	O
CD4	B-GP
+	O
T	O
cells	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
,	O
total	O
HIV	B-OG
DNA	O
and	O
2	O
-	O
LTR	O
circles	O
as	O
well	O
as	O
cell	O
-	O
associated	O
unspliced	O
(	O
CA	O
-	O
US	O
)	O
HIV	B-OG
RNA	O
(	O
Fig	O
1B	O
and	O
S1	O
Table	O
).	O

Total	O
HIV	B-OG
DNA	O
and	O
cell	O
-	O
associated	O
US	O
HIV	B-OG
RNA	O
were	O
detected	O
in	O
all	O
samples	O
tested	O
,	O
whereas	O
integrated	O
HIV	B-OG
DNA	O
and	O
2	O
-	O
LTR	O
circles	O
were	O
detected	O
in	O
98	O
%,	O
and	O
80	O
%	O
of	O
the	O
samples	O
,	O
respectively	O
.	O

We	O
evaluated	O
the	O
association	O
between	O
markers	O
of	O
HIV	B-OG
persistence	O
and	O
the	O
frequencies	O
of	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
ICs	B-GP
using	O
a	O
negative	O
binomial	O
regression	O
model	O
that	O
was	O
adjusted	O
for	O
current	O
and	O
nadir	O
CD4	B-GP
+	O
T	O
-	O
cell	O
counts	O
when	O
indicated	O
(	O
Table	O
2	O
and	O
S2	O
–	O
S4	O
Tables	O
).	O

Using	O
these	O
tailored	O
analytical	O
methods	O
for	O
HIV	B-OG
reservoir	O
measurements	O
,	O
we	O
identified	O
3	O
ICs	B-GP
for	O
which	O
the	O
expression	O
on	O
CD4	B-GP
+	O
T	O
cells	O
was	O
statistically	O
significantly	O
associated	O
with	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
,	O
namely	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
(	O
Fig	O
1C	O
–	O
1E	O
and	O
Table	O
2	O
).	O

These	O
correlations	O
persisted	O
after	O
adjusting	O
for	O
nadir	O
CD4	B-GP
+	O
T	O
-	O
cell	O
counts	O
but	O
were	O
no	O
longer	O
significant	O
after	O
adjusting	O
for	O
current	O
CD4	B-GP
+	O
T	O
-	O
cell	O
count	O
,	O
a	O
clinical	O
parameter	O
strongly	O
associated	O
with	O
the	O
size	O
of	O
the	O
reservoir	O
during	O
ART	O
[	O
6	O
,	O
37	O
,	O
38	O
].	O

Negative	O
binomial	O
regression	O
models	O
to	O
assess	O
the	O
relationship	O
between	O
integrated	O
HIV	B-OG
DNA	O
and	O
IC	O
expression	O
on	O
CD4	B-GP
+	O
T	O
cells	O
.	O

Outcome	O

Predictor	O
a	O

Unadjusted	O

Adjusted	O
for	O
Current	O
CD4	B-GP

Adjusted	O
for	O
Nadir	O
CD4	B-GP

Result	O
(	O
95	O
%	O
CI	O
)	O
c	O
,	O
d	O

p	O
-	O
value	O
e	O

Result	O
(	O
95	O
%	O
CI	O
)	O

p	O
-	O
value	O

Result	O
(	O
95	O
%	O
CI	O
)	O

p	O
-	O
value	O

Integrated	O
HIV	B-OG
DNA	O
b	O

PD1	O
+	O

1	O
.	O
43	O
(	O
1	O
.	O
08	O
to	O
1	O
.	O
90	O
)	O

0	O
.	O
012	O

1	O
.	O
17	O
(	O
0	O
.	O
91	O
to	O
1	O
.	O
50	O
)	O

0	O
.	O
220	O

1	O
.	O
39	O
(	O
1	O
.	O
05	O
to	O
1	O
.	O
82	O
)	O

0	O
.	O
020	O

CTLA	B-GP
-	I-GP
4	I-GP
+	O

1	O
.	O
50	O
(	O
0	O
.	O
90	O
to	O
2	O
.	O
51	O
)	O

0	O
.	O
120	O

1	O
.	O
18	O
(	O
0	O
.	O
73	O
to	O
1	O
.	O
91	O
)	O

0	O
.	O
500	O

1	O
.	O
43	O
(	O
0	O
.	O
88	O
to	O
2	O
.	O
35	O
)	O

0	O
.	O
150	O

LAG	B-GP
-	I-GP
3	I-GP
+	O

1	O
.	O
62	O
(	O
1	O
.	O
07	O
to	O
2	O
.	O
45	O
)	O

0	O
.	O
022	O

1	O
.	O
07	O
(	O
0	O
.	O
69	O
to	O
1	O
.	O
65	O
)	O

0	O
.	O
760	O

1	O
.	O
58	O
(	O
1	O
.	O
07	O
to	O
2	O
.	O
35	O
)	O

0	O
.	O
023	O

TIGIT	B-GP
+	O

1	O
.	O
91	O
(	O
1	O
.	O
11	O
to	O
3	O
.	O
28	O
)	O

0	O
.	O
020	O

1	O
.	O
54	O
(	O
0	O
.	O
91	O
to	O
2	O
.	O
60	O
)	O

0	O
.	O
110	O

1	O
.	O
87	O
(	O
1	O
.	O
10	O
to	O
3	O
.	O
16	O
)	O

0	O
.	O
020	O

TIM	B-GP
-	I-GP
3	I-GP
+	O

1	O
.	O
28	O
(	O
0	O
.	O
83	O
to	O
1	O
.	O
97	O
)	O

0	O
.	O
260	O

1	O
.	O
24	O
(	O
0	O
.	O
85	O
to	O
1	O
.	O
80	O
)	O

0	O
.	O
260	O

1	O
.	O
38	O
(	O
0	O
.	O
89	O
to	O
2	O
.	O
14	O
)	O

0	O
.	O
160	O

CD160	B-GP
+	O

1	O
.	O
07	O
(	O
0	O
.	O
82	O
to	O
1	O
.	O
39	O
)	O

0	O
.	O
620	O

0	O
.	O
90	O
(	O
0	O
.	O
69	O
to	O
1	O
.	O
17	O
)	O

0	O
.	O
420	O

1	O
.	O
13	O
(	O
0	O
.	O
86	O
to	O
1	O
.	O
48	O
)	O

0	O
.	O
370	O

2B4	B-GP
+	O

1	O
.	O
06	O
(	O
0	O
.	O
83	O
to	O
1	O
.	O
36	O
)	O

0	O
.	O
630	O

0	O
.	O
92	O
(	O
0	O
.	O
71	O
to	O
1	O
.	O
18	O
)	O

0	O
.	O
500	O

1	O
.	O
10	O
(	O
0	O
.	O
87	O
to	O
1	O
.	O
39	O
)	O

0	O
.	O
440	O

a	O
Percentage	O
CD4	B-GP
+	O
T	O
cells	O
that	O
express	O
Immune	B-GP
Checkpoint	I-GP
Molecules	I-GP

b	O
Integrated	O
HIV	B-OG
DNA	O
units	O
(	O
copies	O
/	O
million	O
CD4	B-GP
+	O
T	O
cells	O
)	O

c	O
95	O
%	O
CI	O
=	O
95	O
%	O
confidence	O
interval	O

d	O
Result	O
interpretation	O
:	O
fold	O
-	O
change	O
in	O
the	O
outcome	O
(	O
marker	O
of	O
HIV	B-OG
persistence	O
)	O
for	O
each	O
unit	O
change	O
of	O
the	O
predictor	O
(	O
Immune	B-GP
Checkpoint	I-GP
Molecules	I-GP
).	O

All	O
predictors	O
were	O
log2	O
transformed	O
,	O
so	O
results	O
here	O
are	O
interpreted	O
as	O
the	O
change	O
in	O
the	O
outcome	O
for	O
each	O
doubling	O
of	O
the	O
predictor	O

e	O
Statistically	O
significant	O
p	O
values	O
are	O
<	O
0	O
.	O
05	O
and	O
are	O
bold	O

The	O
frequency	O
of	O
PD	B-GP
-	I-GP
1	I-GP
expressing	O
CD4	B-GP
+	O
T	O
cells	O
was	O
also	O
associated	O
with	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
harboring	O
total	O
HIV	B-OG
DNA	O
(	O
S3	O
Table	O
),	O
but	O
only	O
marginally	O
(	O
1	O
.	O
23	O
-	O
fold	O
effect	O
,	O
p	O
=	O
0	O
.	O
07	O
)	O
when	O
the	O
model	O
was	O
adjusted	O
for	O
current	O
CD4	B-GP
+	O
T	O
-	O
cell	O
count	O
.	O

CA	O
-	O
US	O
HIV	B-OG
RNA	O
and	O
2	O
-	O
LTR	O
circles	O
did	O
not	O
show	O
statistically	O
significant	O
correlation	O
with	O
any	O
IC	O
expression	O
levels	O
,	O
with	O
the	O
exception	O
of	O
a	O
negative	O
association	O
between	O
the	O
frequency	O
of	O
CD160	B-GP
+	O
CD4	B-GP
+	O
T	O
cells	O
and	O
2	O
-	O
LTR	O
circles	O
that	O
remained	O
statistically	O
significant	O
after	O
adjusting	O
for	O
current	O
and	O
nadir	O
CD4	B-GP
+	O
T	O
-	O
cell	O
count	O
(	O
S3	O
and	O
S4	O
Tables	O
).	O

Co	O
-	O
expression	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
is	O
a	O
marker	O
of	O
HIV	B-OG
persistence	O
during	O
ART	O

ICs	B-GP
are	O
co	O
-	O
expressed	O
on	O
exhausted	O
CD4	B-GP
+	O
and	O
CD8	B-GP
+	O
T	O
cells	O
during	O
untreated	O
HIV	B-DS
infection	I-DS
[	O
39	O
].	O

Using	O
a	O
Boolean	O
gating	O
strategy	O
,	O
we	O
determined	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
co	O
-	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
and	O
/	O
or	O
TIGIT	B-GP
and	O
/	O
or	O
LAG	B-GP
-	I-GP
3	I-GP
in	O
our	O
cohort	O
of	O
48	O
HIV	B-OG
-	O
infected	O
participants	O
receiving	O
suppressive	O
ART	O
(	O
Fig	O
2A	O
and	O
2B	O
).	O

The	O
majority	O
of	O
CD4	B-GP
+	O
T	O
cells	O
did	O
not	O
express	O
any	O
of	O
these	O
markers	O
(	O
median	O
(	O
IQR	O
)	O
of	O
65	O
.	O
8	O
%	O
(	O
59	O
.	O
0	O
–	O
72	O
.	O
4	O
))	O
(	O
S6	O
Table	O
).	O

Less	O
than	O
10	O
%	O
(	O
8	O
.	O
5	O
%)	O
of	O
CD4	B-GP
+	O
T	O
cells	O
expressed	O
more	O
than	O
one	O
of	O
these	O
markers	O
and	O
0	O
.	O
9	O
%	O
simultaneously	O
expressed	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
.	O

We	O
further	O
assessed	O
if	O
the	O
frequency	O
of	O
these	O
discrete	O
CD4	B-GP
+	O
T	O
-	O
cell	O
subsets	O
was	O
associated	O
with	O
markers	O
of	O
HIV	B-OG
persistence	O
.	O

Using	O
the	O
negative	O
binomial	O
regression	O
model	O
,	O
we	O
found	O
that	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
not	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
was	O
strongly	O
and	O
negatively	O
correlated	O
to	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
(	O
p	O
=	O
0	O
.	O
002	O
,	O
Table	O
3	O
and	O
Fig	O
2C	O
).	O

Conversely	O
,	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cell	O
co	O
-	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
was	O
strongly	O
and	O
positively	O
associated	O
with	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
(	O
p	O
=	O
0	O
.	O
001	O
,	O
Table	O
3	O
and	O
Fig	O
2F	O
).	O

Interestingly	O
,	O
the	O
frequencies	O
of	O
CD4	B-GP
+	O
T	O
cells	O
co	O
-	O
expressing	O
TIGIT	B-GP
with	O
either	O
PD	B-GP
-	I-GP
1	I-GP
or	O
LAG	B-GP
-	I-GP
3	I-GP
were	O
also	O
positively	O
associated	O
with	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
(	O
p	O
=	O
0	O
.	O
002	O
and	O
p	O
=	O
0	O
.	O
029	O
respectively	O
,	O
Table	O
3	O
and	O
Fig	O
2D	O
and	O
2E	O
).	O

Although	O
several	O
of	O
these	O
associations	O
were	O
less	O
or	O
no	O
longer	O
statistically	O
significant	O
when	O
the	O
model	O
was	O
adjusted	O
for	O
the	O
current	O
CD4	B-GP
+	O
T	O
-	O
cell	O
count	O
,	O
the	O
association	O
between	O
the	O
size	O
of	O
the	O
HIV	B-OG
reservoir	O
and	O
the	O
frequency	O
of	O
triple	O
positive	O
cells	O
(	O
PD	B-GP
-	I-GP
1	I-GP
+,	O
LAG	B-GP
-	I-GP
3	I-GP
+	O
and	O
TIGIT	B-GP
+)	O
remained	O
statistically	O
significant	O
after	O
adjustment	O
(	O
p	O
=	O
0	O
.	O
038	O
).	O

Adjusting	O
for	O
duration	O
of	O
ART	O
did	O
not	O
produce	O
any	O
substantial	O
changes	O
to	O
the	O
results	O
from	O
the	O
unadjusted	O
analysis	O
(	O
all	O
fold	O
-	O
effects	O
adjusted	O
for	O
ART	O
duration	O
within	O
7	O
%	O
of	O
those	O
unadjusted	O
).	O

All	O
together	O
,	O
these	O
results	O
indicate	O
that	O
the	O
co	O
-	O
expression	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
identifies	O
a	O
unique	O
subset	O
of	O
CD4	B-GP
+	O
T	O
cells	O
that	O
strongly	O
predicts	O
the	O
frequency	O
of	O
cells	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
during	O
ART	O
.	O

Co	O
-	O
expression	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
is	O
a	O
marker	O
of	O
HIV	B-OG
persistence	O
during	O
ART	O
.	O

(	O
A	O
)	O
Frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
co	O
-	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
and	O
/	O
or	O
TIGIT	B-GP
and	O
/	O
or	O
LAG	B-GP
-	I-GP
3	I-GP
(	O
PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	B-GP
/	O
LAG	B-GP
-	I-GP
3	I-GP
triple	O
–(	O
P	O
-	O
T	O
-	O
L	O
-),	O
PD	B-GP
-	I-GP
1	I-GP
single	O
+	O
(	O
P	O
+),	O
TIGIT	B-GP
single	O
+	O
(	O
T	O
+),	O
LAG	B-GP
-	I-GP
3	I-GP
single	O
+	O
(	O
L	O
+),	O
PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	B-GP
double	O
+	O
(	O
P	O
+	O
T	O
+),	O
TIGIT	B-GP
/	O
LAG	B-GP
-	I-GP
3	I-GP
double	O
+	O
(	O
T	O
+	O
L	O
+),	O
PD	B-GP
-	I-GP
1	I-GP
/	O
LAG	B-GP
-	I-GP
3	I-GP
double	O
+	O
(	O
P	O
+	O
L	O
+)	O
and	O
PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	B-GP
/	O
LAG	B-GP
-	I-GP
3	I-GP
triple	O
+	O
(	O
P	O
+	O
T	O
+	O
L	O
+))	O
determined	O
by	O
Boolean	O
gating	O
in	O
cohort	O
1	O
(	O
n	O
=	O
48	O
).	O

Horizontal	O
bars	O
indicate	O
median	O
values	O
with	O
interquartile	O
ranges	O
.	O

(	O
B	O
)	O
Venn	O
diagram	O
showing	O
the	O
pattern	O
of	O
co	O
-	O
expression	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
.	O

(	O
C	O
),	O
(	O
D	O
),	O
(	O
E	O
),	O
(	O
F	O
)	O
Associations	O
between	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
and	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
none	O
of	O
these	O
markers	O
(	O
triple	O
–),	O
PD	B-GP
-	I-GP
1	I-GP
and	O
TIGIT	B-GP
(	O
double	O
+),	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
(	O
double	O
+)	O
and	O
PD	B-GP
-	I-GP
1	I-GP
and	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
(	O
triple	O
+),	O
respectively	O
.	O

P	O
values	O
were	O
obtained	O
from	O
negative	O
binomial	O
regression	O
analysis	O
.	O

Effect	O
sizes	O
for	O
the	O
associations	O
are	O
as	O
follows	O
:	O
(	O
C	O
)	O
0	O
.	O
69	O
-	O
fold	O
-	O
change	O
in	O
integrated	O
HIV	B-OG
DNA	O
for	O
1	O
point	O
increase	O
in	O
percentage	O
of	O
PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	B-GP
/	O
LAG	B-GP
-	I-GP
3	I-GP
triple	O
—	O
CD4	B-GP
+	O
T	O
cells	O
,	O
(	O
D	O
)	O
1	O
.	O
18	O
-	O
fold	O
-	O
change	O
in	O
integrated	O
HIV	B-OG
DNA	O
for	O
1	O
point	O
increase	O
in	O
percentage	O
of	O
PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	B-GP
double	O
+	O
CD4	B-GP
+	O
T	O
cells	O
,	O
(	O
E	O
)	O
1	O
.	O
30	O
-	O
fold	O
-	O
change	O
in	O
integrated	O
HIV	B-OG
DNA	O
for	O
1	O
point	O
increase	O
in	O
percentage	O
of	O
TIGIT	B-GP
/	O
LAG	B-GP
-	I-GP
3	I-GP
double	O
+	O
CD4	B-GP
+	O
T	O
cells	O
and	O
(	O
F	O
)	O
1	O
.	O
94	O
-	O
fold	O
-	O
change	O
in	O
integrated	O
HIV	B-OG
DNA	O
for	O
1	O
point	O
increase	O
in	O
percentage	O
of	O
PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	B-GP
/	O
LAG	B-GP
-	I-GP
3	I-GP
triple	O
+	O
CD4	B-GP
+	O
T	O
cells	O
.	O

Open	O
circles	O
represent	O
the	O
limit	O
of	O
detection	O
in	O
the	O
negative	O
samples	O
(	O
based	O
on	O
cell	O
input	O
).	O

Negative	O
binomial	O
regression	O
models	O
to	O
assess	O
the	O
relationship	O
between	O
Integrated	O
HIV	B-OG
DNA	O
and	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
and	O
/	O
or	O
TIGIT	B-GP
and	O
/	O
or	O
LAG	B-GP
-	I-GP
3	I-GP
.	O

Outcome	O

Predictor	O
a	O

Unadjusted	O

Adjusted	O
for	O
Current	O
CD4	B-GP

Adjusted	O
for	O
Nadir	O
CD4	B-GP

Adjusted	O
for	O
ART	O
duration	O

Result	O
(	O
95	O
%	O
CI	O
)	O
c	O
,	O
d	O

p	O
-	O
value	O
e	O

Result	O
(	O
95	O
%	O
CI	O
)	O

p	O
-	O
value	O

Result	O
(	O
95	O
%	O
CI	O
)	O

p	O
-	O
value	O

Result	O
(	O
95	O
%	O
CI	O
)	O

p	O
-	O
value	O

Integrated	O
HIV	B-OG
DNA	O
b	O

PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	B-GP
/	O
LAG	B-GP
-	I-GP
3	I-GP
triple	O
–	O
f	O

0	O
.	O
69	O
(	O
0	O
.	O
54	O
to	O
0	O
.	O
87	O
)	O

0	O
.	O
002	O

0	O
.	O
82	O
(	O
0	O
.	O
65	O
to	O
1	O
.	O
03	O
)	O

0	O
.	O
084	O

0	O
.	O
70	O
(	O
0	O
.	O
56	O
to	O
0	O
.	O
86	O
)	O

0	O
.	O
001	O

0	O
.	O
68	O
(	O
0	O
.	O
54	O
–	O
0	O
.	O
85	O
)	O

0	O
.	O
001	O

PD	B-GP
-	I-GP
1	I-GP
single	O
+	O
f	O

1	O
.	O
24	O
(	O
0	O
.	O
90	O
to	O
1	O
.	O
70	O
)	O

0	O
.	O
187	O

1	O
.	O
09	O
(	O
0	O
.	O
80	O
to	O
1	O
.	O
48	O
)	O

0	O
.	O
578	O

1	O
.	O
28	O
(	O
0	O
.	O
94	O
to	O
1	O
.	O
75	O
)	O

0	O
.	O
118	O

1	O
.	O
32	O
(	O
0	O
.	O
93	O
–	O
1	O
.	O
88	O
)	O

0	O
.	O
12	O

TIGIT	B-GP
single	O
+	O

1	O
.	O
06	O
(	O
0	O
.	O
99	O
to	O
1	O
.	O
14	O
)	O

0	O
.	O
106	O

1	O
.	O
05	O
(	O
0	O
.	O
98	O
to	O
1	O
.	O
12	O
)	O

0	O
.	O
210	O

1	O
.	O
06	O
(	O
0	O
.	O
99	O
to	O
1	O
.	O
13	O
)	O

0	O
.	O
111	O

1	O
.	O
06	O
(	O
0	O
.	O
98	O
–	O
1	O
.	O
14	O
)	O

0	O
.	O
13	O

LAG	B-GP
-	I-GP
3	I-GP
single	O
+	O

1	O
.	O
00	O
(	O
0	O
.	O
95	O
to	O
1	O
.	O
05	O
)	O

0	O
.	O
963	O

0	O
.	O
97	O
(	O
0	O
.	O
92	O
to	O
1	O
.	O
02	O
)	O

0	O
.	O
176	O

1	O
.	O
00	O
(	O
0	O
.	O
94	O
to	O
1	O
.	O
05	O
)	O

0	O
.	O
848	O

1	O
.	O
00	O
(	O
0	O
.	O
95	O
–	O
1	O
.	O
05	O
)	O

0	O
.	O
86	O

PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	B-GP
double	O
+	O

1	O
.	O
18	O
(	O
1	O
.	O
07	O
to	O
1	O
.	O
31	O
)	O

0	O
.	O
002	O

1	O
.	O
13	O
(	O
1	O
.	O
00	O
to	O
1	O
.	O
26	O
)	O

0	O
.	O
042	O

1	O
.	O
17	O
(	O
1	O
.	O
06	O
to	O
1	O
.	O
30	O
)	O

0	O
.	O
003	O

1	O
.	O
19	O
(	O
1	O
.	O
07	O
–	O
1	O
.	O
32	O
)	O

0	O
.	O
001	O

TIGIT	B-GP
/	O
LAG	B-GP
-	I-GP
3	I-GP
double	O
+	O

1	O
.	O
30	O
(	O
1	O
.	O
03	O
to	O
1	O
.	O
64	O
)	O

0	O
.	O
029	O

1	O
.	O
16	O
(	O
0	O
.	O
97	O
to	O
1	O
.	O
38	O
)	O

0	O
.	O
100	O

1	O
.	O
27	O
(	O
1	O
.	O
04	O
to	O
1	O
.	O
55	O
)	O

0	O
.	O
018	O

1	O
.	O
29	O
(	O
1	O
.	O
02	O
–	O
1	O
.	O
65	O
)	O

0	O
.	O
037	O

LAG	B-GP
-	I-GP
3	I-GP
/	O
PD	B-GP
-	I-GP
1	I-GP
double	O
+	O

1	O
.	O
08	O
(	O
0	O
.	O
96	O
to	O
1	O
.	O
23	O
)	O

0	O
.	O
206	O

1	O
.	O
01	O
(	O
0	O
.	O
88	O
to	O
1	O
.	O
16	O
)	O

0	O
.	O
910	O

1	O
.	O
09	O
(	O
0	O
.	O
96	O
to	O
1	O
.	O
25	O
)	O

0	O
.	O
175	O

1	O
.	O
11	O
(	O
0	O
.	O
96	O
–	O
1	O
.	O
23	O
)	O

0	O
.	O
15	O

PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	B-GP
/	O
LAG	B-GP
-	I-GP
3	I-GP
triple	O
+	O

1	O
.	O
94	O
(	O
1	O
.	O
33	O
to	O
2	O
.	O
83	O
)	O

0	O
.	O
001	O

1	O
.	O
45	O
(	O
1	O
.	O
02	O
to	O
2	O
.	O
05	O
)	O

0	O
.	O
038	O

1	O
.	O
86	O
(	O
1	O
.	O
26	O
to	O
2	O
.	O
72	O
)	O

0	O
.	O
002	O

1	O
.	O
92	O
(	O
1	O
.	O
31	O
–	O
2	O
.	O
81	O
)	O

0	O
.	O
001	O

a	O
Percentage	O
CD4	B-GP
+	O
T	O
cells	O
that	O
express	O
Immune	B-GP
Checkpoint	I-GP
Molecules	I-GP

b	O
Integrated	O
HIV	B-OG
DNA	O
units	O
(	O
copies	O
/	O
million	O
CD4	B-GP
+	O
T	O
cells	O
)	O

c	O
95	O
%	O
CI	O
=	O
95	O
%	O
confidence	O
interval	O

d	O
Result	O
interpretation	O
:	O
fold	O
-	O
change	O
in	O
the	O
outcome	O
(	O
marker	O
of	O
HIV	B-OG
persistence	O
)	O
for	O
each	O
one	O
point	O
increase	O
in	O
the	O
percent	O
of	O
cells	O
expressing	O
the	O
predictor	O
(	O
PD	B-GP
-	I-GP
1	I-GP
and	O
/	O
or	O
TIGIT	B-GP
and	O
/	O
or	O
LAG	B-GP
-	I-GP
3	I-GP
)	O

e	O
Statistically	O
significant	O
p	O
values	O
are	O
<	O
0	O
.	O
05	O
and	O
are	O
bold	O

f	O
These	O
predictors	O
vary	O
more	O
than	O
others	O
,	O
so	O
results	O
are	O
scaled	O
to	O
be	O
per	O
10	O
point	O
increase	O
in	O
percent	O
of	O
cells	O
,	O
rather	O
than	O
per	O
one	O
point	O
increase	O

When	O
the	O
negative	O
binomial	O
regression	O
model	O
was	O
used	O
to	O
assess	O
the	O
relationship	O
between	O
Total	O
HIV	B-OG
DNA	O
,	O
2	O
-	O
LTR	O
circles	O
,	O
CA	O
-	O
US	O
RNA	O
and	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
and	O
/	O
or	O
TIGIT	B-GP
and	O
/	O
or	O
LAG	B-GP
-	I-GP
3	I-GP
,	O
no	O
association	O
show	O
statistically	O
significant	O
,	O
with	O
the	O
exception	O
of	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
harboring	O
total	O
HIV	B-OG
DNA	O
and	O
the	O
frequency	O
of	O
PD	B-GP
-	I-GP
1	I-GP
single	O
+	O
(	O
p	O
=	O
0	O
.	O
005	O
,	O
1	O
.	O
10	O
-	O
fold	O
-	O
change	O
in	O
total	O
HIV	B-OG
DNA	O
for	O
1	O
point	O
increase	O
in	O
percentage	O
of	O
PD	B-GP
-	I-GP
1	I-GP
single	O
+	O
CD4	B-GP
+	O
T	O
cells	O
)	O
and	O
PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	B-GP
double	O
+	O
CD4	B-GP
+	O
T	O
cells	O
(	O
p	O
=	O
0	O
.	O
017	O
,	O
1	O
.	O
40	O
-	O
fold	O
-	O
change	O
in	O
total	O
HIV	B-OG
DNA	O
for	O
1	O
point	O
increase	O
in	O
percentage	O
of	O
PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	B-GP
double	O
+	O
CD4	B-GP
+	O
T	O
cells	O
).	O

Expressions	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
are	O
associated	O
with	O
HIV	B-OG
-	O
infected	O
cells	O
in	O
distinct	O
memory	O
CD4	B-GP
+	O
T	O
-	O
cell	O
subsets	O
during	O
ART	O

HIV	B-OG
persists	O
preferentially	O
in	O
memory	O
CD4	B-GP
+	O
T	O
-	O
cell	O
subsets	O
[	O
6	O
–	O
8	O
].	O

To	O
determine	O
the	O
role	O
played	O
by	O
ICs	B-GP
in	O
each	O
individual	O
CD4	B-GP
+	O
T	O
-	O
cell	O
memory	O
subset	O
,	O
we	O
first	O
analyzed	O
the	O
expression	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
,	O
the	O
3	O
ICs	B-GP
we	O
identified	O
to	O
be	O
associated	O
with	O
HIV	B-OG
persistence	O
,	O
on	O
naïve	O
(	O
TN	O
),	O
central	O
memory	O
(	O
TCM	O
),	O
transitional	O
memory	O
(	O
TTM	O
),	O
effector	O
memory	O
(	O
TEM	O
)	O
and	O
terminally	O
differentiated	O
(	O
TTD	O
)	O
cells	O
in	O
48	O
HIV	B-OG
-	O
infected	O
participants	O
(	O
Cohort	O
1	O
:	O
clinical	O
characteristics	O
in	O
Table	O
1	O
)	O
(	O
Fig	O
3A	O
,	O
3B	O
and	O
3C	O
respectively	O
).	O

As	O
expected	O
,	O
TN	O
cells	O
expressed	O
low	O
levels	O
of	O
these	O
ICs	B-GP
.	O

The	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
or	O
LAG	B-GP
-	I-GP
3	I-GP
increased	O
with	O
differentiation	O
,	O
with	O
TEM	O
cells	O
displaying	O
the	O
highest	O
levels	O
of	O
expression	O
of	O
these	O
markers	O
.	O

The	O
highest	O
frequency	O
of	O
TIGIT	B-GP
+	O
cells	O
was	O
found	O
within	O
the	O
TTM	O
subset	O
.	O

These	O
results	O
demonstrated	O
that	O
the	O
subsets	O
of	O
memory	O
cells	O
that	O
were	O
previously	O
shown	O
to	O
harbor	O
persistent	O
HIV	B-OG
during	O
ART	O
express	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
.	O

PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
identify	O
HIV	B-OG
-	O
infected	O
cells	O
in	O
distinct	O
memory	O
CD4	B-GP
+	O
T	O
-	O
cell	O
subsets	O
during	O
ART	O
.	O

(	O
A	O
),	O
(	O
B	O
),	O
(	O
C	O
)	O
Frequencies	O
of	O
memory	O
CD4	B-GP
+	O
T	O
-	O
cell	O
subsets	O
(	O
naïve	O
(	O
TN	O
),	O
central	O
memory	O
(	O
TCM	O
),	O
transitional	O
memory	O
(	O
TTM	O
),	O
effector	O
memory	O
(	O
TEM	O
)	O
and	O
terminally	O
differentiated	O
(	O
TD	O
))	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
or	O
LAG	B-GP
-	I-GP
3	I-GP
,	O
respectively	O
.	O

Horizontal	O
bars	O
indicate	O
median	O
values	O
with	O
interquartile	O
ranges	O
.	O

(	O
D	O
),	O
(	O
E	O
),	O
(	O
F	O
)	O
Frequencies	O
of	O
cells	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
in	O
TCM	O
,	O
TTM	O
and	O
TEM	O
CD4	B-GP
+	O
T	O
-	O
cell	O
subsets	O
sorted	O
based	O
on	O
their	O
expression	O
of	O
PD	B-GP
-	I-GP
1	I-GP
(	O
n	O
=	O
12	O
),	O
TIGIT	B-GP
(	O
n	O
=	O
9	O
)	O
or	O
LAG	B-GP
-	I-GP
3	I-GP
(	O
n	O
=	O
7	O
),	O
respectively	O
.	O

Results	O
are	O
expressed	O
as	O
the	O
HIV	B-OG
copy	O
number	O
in	O
million	O
cells	O
of	O
a	O
given	O
subset	O
.	O

P	O
values	O
were	O
obtained	O
from	O
negative	O
binomial	O
regression	O
analysis	O
.	O

Significant	O
differences	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
are	O
designated	O
by	O
a	O
p	O
value	O
in	O
bold	O
.	O

Open	O
circles	O
represent	O
the	O
limit	O
of	O
detection	O
in	O
the	O
negative	O
samples	O
(	O
based	O
on	O
cell	O
input	O
).	O

To	O
determine	O
whether	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
identify	O
cells	O
more	O
likely	O
to	O
carry	O
persistent	O
HIV	B-OG
in	O
virally	O
suppressed	O
participants	O
,	O
individual	O
memory	O
CD4	B-GP
+	O
T	O
-	O
cell	O
subsets	O
were	O
sorted	O
based	O
on	O
their	O
expression	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
or	O
LAG	B-GP
-	I-GP
3	I-GP
in	O
a	O
subset	O
of	O
subjects	O
who	O
underwent	O
leukapheresis	O
(	O
Cohort	O
2	O
:	O
clinical	O
characteristics	O
in	O
Table	O
1	O
)	O
and	O
the	O
results	O
were	O
analyzed	O
by	O
negative	O
binomial	O
regression	O
model	O
(	O
S5	O
Table	O
).	O

The	O
frequency	O
of	O
cells	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
was	O
moderately	O
higher	O
in	O
PD	B-GP
-	I-GP
1	I-GP
expressing	O
TTM	O
when	O
compared	O
to	O
their	O
PD	B-GP
-	I-GP
1	I-GP
negative	O
counterparts	O
(	O
p	O
=	O
0	O
.	O
053	O
,	O
fold	O
-	O
difference	O
=	O
1	O
.	O
5	O
)	O
(	O
Fig	O
3D	O
).	O

TEM	O
cells	O
expressing	O
TIGIT	B-GP
were	O
enriched	O
for	O
integrated	O
genomes	O
when	O
compared	O
to	O
their	O
TIGIT	B-GP
-	O
counterparts	O
(	O
p	O
=	O
0	O
.	O
001	O
,	O
fold	O
-	O
difference	O
=	O
2	O
.	O
7	O
)	O
(	O
Fig	O
3E	O
).	O

Finally	O
,	O
all	O
the	O
memory	O
CD4	B-GP
+	O
T	O
-	O
cell	O
subsets	O
(	O
TCM	O
,	O
TTM	O
and	O
TEM	O
cells	O
)	O
expressing	O
LAG	B-GP
-	I-GP
3	I-GP
were	O
enriched	O
for	O
integrated	O
HIV	B-OG
DNA	O
when	O
compared	O
to	O
their	O
negative	O
counterparts	O
(	O
p	O
<	O
0	O
.	O
0001	O
,	O
fold	O
-	O
difference	O
=	O
1	O
.	O
9	O
,	O
p	O
=	O
0	O
.	O
003	O
,	O
fold	O
-	O
difference	O
=	O
1	O
.	O
8	O
and	O
p	O
=	O
0	O
.	O
030	O
,	O
fold	O
-	O
difference	O
=	O
2	O
.	O
5	O
respectively	O
)	O
(	O
Fig	O
3F	O
).	O

All	O
together	O
these	O
results	O
indicate	O
that	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
enrich	O
for	O
infected	O
cells	O
in	O
distinct	O
memory	O
CD4	B-GP
+	O
T	O
-	O
cell	O
subsets	O
in	O
individuals	O
on	O
ART	O
.	O

We	O
calculated	O
the	O
contribution	O
of	O
cells	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
or	O
LAG	B-GP
-	I-GP
3	I-GP
to	O
the	O
total	O
reservoir	O
by	O
taking	O
into	O
account	O
the	O
frequency	O
of	O
these	O
subsets	O
within	O
the	O
CD4	B-GP
compartment	O
and	O
their	O
relative	O
infection	B-DS
frequencies	O
.	O

The	O
mean	O
contributions	O
of	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
were	O
29	O
%,	O
34	O
%	O
and	O
31	O
%,	O
respectively	O
(	O
S2	O
Fig	O
).	O

As	O
a	O
comparator	O
,	O
TCM	O
,	O
TTM	O
and	O
TEM	O
cells	O
contributed	O
43	O
%,	O
27	O
%	O
and	O
24	O
%	O
to	O
the	O
pool	O
of	O
infected	O
cells	O
in	O
these	O
same	O
virally	O
suppressed	O
individuals	O
.	O

These	O
data	O
indicate	O
that	O
a	O
third	O
of	O
the	O
reservoir	O
is	O
encompassed	O
in	O
cells	O
expressing	O
each	O
individual	O
marker	O
.	O

Co	O
-	O
expression	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
highly	O
enriches	O
in	O
HIV	B-OG
-	O
infected	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
during	O
ART	O

We	O
then	O
determined	O
if	O
the	O
combination	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
would	O
further	O
enrich	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
for	O
HIV	B-OG
-	O
infected	O
cells	O
during	O
ART	O
.	O

The	O
average	O
frequency	O
of	O
cells	O
expressing	O
0	O
,	O
1	O
,	O
2	O
or	O
3	O
of	O
these	O
markers	O
in	O
the	O
memory	O
CD4	B-GP
+	O
T	O
compartment	O
(	O
CD45RA	B-GP
-)	O
from	O
our	O
cohort	O
of	O
48	O
individuals	O
(	O
Table	O
1	O
)	O
indicated	O
that	O
an	O
average	O
of	O
33	O
%	O
of	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
expressed	O
one	O
of	O
the	O
3	O
IC	O
only	O
,	O
12	O
%	O
expressed	O
2	O
and	O
2	O
%	O
expressed	O
the	O
3	O
markers	O
simultaneously	O
.	O

Large	O
numbers	O
of	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
were	O
sorted	O
based	O
on	O
their	O
expression	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
from	O
5	O
individuals	O
.	O

The	O
combination	O
of	O
these	O
3	O
markers	O
allowed	O
us	O
to	O
sort	O
eight	O
subsets	O
of	O
cells	O
to	O
high	O
purity	O
,	O
namely	O
PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	B-GP
/	O
LAG	B-GP
-	I-GP
3	I-GP
triple	O
-,	O
PD	B-GP
-	I-GP
1	I-GP
single	O
+,	O
TIGIT	B-GP
single	O
+,	O
LAG	B-GP
-	I-GP
3	I-GP
single	O
+,	O
PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	B-GP
double	O
+,	O
TIGIT	B-GP
/	O
LAG	B-GP
-	I-GP
3	I-GP
double	O
+,	O
PD	B-GP
-	I-GP
1	I-GP
/	O
LAG	B-GP
-	I-GP
3	I-GP
double	O
+	O
and	O
PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	B-GP
/	O
LAG	B-GP
-	I-GP
3	I-GP
triple	O
+	O
cells	O
.	O

The	O
frequency	O
of	O
cells	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
was	O
measured	O
by	O
qPCR	O
in	O
each	O
sorted	O
subset	O
(	O
S3	O
Fig	O
)	O
and	O
the	O
mean	O
frequency	O
for	O
each	O
category	O
was	O
calculated	O
relative	O
to	O
total	O
CD4	B-GP
+	O
T	O
cells	O
(	O
Fig	O
4B	O
).	O

Memory	O
CD4	B-GP
+	O
T	O
cells	O
showed	O
a	O
gradual	O
enrichment	O
in	O
HIV	B-OG
-	O
infected	O
cells	O
when	O
expressing	O
an	O
increasing	O
number	O
of	O
ICs	B-GP
.	O

Memory	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
simultaneously	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
were	O
enriched	O
for	O
HIV	B-OG
-	O
infected	O
cells	O
up	O
to	O
10	O
times	O
more	O
when	O
compared	O
to	O
total	O
CD4	B-GP
+	O
T	O
cells	O
,	O
with	O
a	O
median	O
fold	O
increase	O
(	O
IQR	O
)	O
of	O
8	O
.	O
15	O
(	O
4	O
.	O
92	O
–	O
9	O
.	O
59	O
).	O

These	O
results	O
demonstrated	O
that	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
a	O
combination	O
of	O
ICs	B-GP
were	O
highly	O
enriched	O
for	O
integrated	O
HIV	B-OG
DNA	O
during	O
ART	O
.	O

Co	O
-	O
expression	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
identifies	O
HIV	B-OG
-	O
infected	O
cells	O
during	O
ART	O
.	O

(	O
A	O
)	O
Pie	O
chart	O
representing	O
the	O
frequencies	O
of	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
co	O
-	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
and	O
/	O
or	O
TIGIT	B-GP
and	O
/	O
or	O
LAG	B-GP
-	I-GP
3	I-GP
in	O
cohort	O
1	O
(	O
n	O
=	O
48	O
).	O

Coloured	O
bars	O
on	O
the	O
right	O
side	O
designate	O
categories	O
of	O
ICs	B-GP
expressing	O
cells	O
:	O
Triple	O
-:	O
PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	B-GP
/	O
LAG	B-GP
-	I-GP
3	I-GP
triple	O
—	O
in	O
blue	O
;	O
single	O
+:	O
PD	B-GP
-	I-GP
1	I-GP
single	O
+,	O
TIGIT	B-GP
single	O
+,	O
LAG	B-GP
-	I-GP
3	I-GP
single	O
+	O
in	O
green	O
;	O
double	O
+:	O
PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	B-GP
double	O
+,	O
TIGIT	B-GP
/	O
LAG	B-GP
-	I-GP
3	I-GP
double	O
+,	O
PD	B-GP
-	I-GP
1	I-GP
/	O
LAG	B-GP
-	I-GP
3	I-GP
double	O
+	O
in	O
orange	O
and	O
triple	O
+:	O
PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	B-GP
/	O
LAG	B-GP
-	I-GP
3	I-GP
triple	O
+	O
in	O
red	O
.	O

(	O
B	O
)	O
Frequency	O
of	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
represented	O
as	O
a	O
fold	O
change	O
over	O
frequency	O
in	O
total	O
CD4	B-GP
+	O
T	O
cells	O
.	O

Mean	O
values	O
and	O
standard	O
deviations	O
from	O
5	O
independent	O
donors	O
are	O
represented	O
(	O
n	O
=	O
5	O
).	O

(	O
C	O
)	O
Frequency	O
of	O
cells	O
harboring	O
inducible	O
msRNA	O
measured	O
by	O
TILDA	O
in	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
any	O
(	O
i	O
.	O
e	O
.	O
at	O
least	O
one	O
)	O
versus	O
none	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
or	O
LAG	B-GP
-	I-GP
3	I-GP
(	O
mLPT	O
+	O
and	O
mLPT	O
-	O
respectively	O
).	O

P	O
value	O
and	O
fold	O
-	O
difference	O
were	O
obtained	O
from	O
a	O
maximum	O
likelihood	O
model	O
.	O

As	O
the	O
majority	O
of	O
HIV	B-OG
genomes	O
,	O
even	O
when	O
integrated	O
,	O
are	O
defective	O
[	O
40	O
],	O
we	O
assessed	O
if	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
identify	O
cells	O
in	O
which	O
HIV	B-OG
production	O
can	O
be	O
induced	O
.	O

As	O
the	O
frequency	O
of	O
triple	O
positive	O
cells	O
was	O
too	O
low	O
to	O
perform	O
this	O
experiment	O
,	O
we	O
sorted	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
(	O
CD45RA	B-GP
-)	O
expressing	O
any	O
(	O
i	O
.	O
e	O
.	O
at	O
least	O
one	O
)	O
versus	O
none	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
or	O
LAG	B-GP
-	I-GP
3	I-GP
(	O
mLPT	O
+	O
and	O
mLPT	O
-	O
respectively	O
).	O

We	O
measured	O
the	O
frequency	O
of	O
cells	O
in	O
each	O
population	O
that	O
transcribe	O
multiply	O
spliced	O
HIV	B-OG
RNA	O
molecules	O
upon	O
induction	O
with	O
PMA	O
/	O
ionomycin	O
using	O
the	O
Tat	O
/	O
rev	O
induced	O
limiting	O
dilution	O
assay	O
(	O
TILDA	O
)	O
[	O
36	O
].	O

Tat	O
/	O
rev	O
transcripts	O
were	O
detectable	O
by	O
TILDA	O
in	O
both	O
cell	O
subsets	O
from	O
all	O
of	O
the	O
8	O
individuals	O
tested	O
.	O

The	O
rate	O
of	O
inducible	O
virus	B-OG
per	O
million	O
cells	O
was	O
estimated	O
in	O
our	O
maximum	O
likelihood	O
model	O
to	O
average	O
3	O
.	O
0	O
-	O
fold	O
higher	O
in	O
mLPT	O
+	O
cells	O
than	O
in	O
mLPT	O
-	O
cells	O
from	O
the	O
same	O
participant	O
(	O
95	O
%	O
CI	O
1	O
.	O
0	O
to	O
9	O
.	O
0	O
,	O
p	O
=	O
0	O
.	O
049	O
,	O
S1C	O
Text	O
)	O
(	O
Fig	O
4C	O
).	O

Taking	O
into	O
account	O
the	O
frequency	O
of	O
these	O
cell	O
subsets	O
,	O
the	O
contribution	O
of	O
cells	O
expressing	O
at	O
least	O
one	O
of	O
these	O
markers	O
to	O
the	O
total	O
pool	O
of	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
infected	O
with	O
inducible	O
HIV	B-OG
genomes	O
was	O
calculated	O
.	O

This	O
contribution	O
ranged	O
from	O
30	O
to	O
98	O
%	O
(	O
median	O
of	O
76	O
%),	O
indicating	O
that	O
the	O
majority	O
of	O
inducible	O
HIV	B-OG
genomes	O
were	O
found	O
in	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
at	O
least	O
one	O
of	O
these	O
markers	O
.	O

These	O
experiments	O
provide	O
evidence	O
that	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
/	O
or	O
LAG	B-GP
-	I-GP
3	I-GP
are	O
enriched	O
for	O
HIV	B-OG
-	O
infected	O
CD4	B-GP
+	O
T	O
cells	O
harboring	O
inducible	O
proviruses	B-OG
during	O
ART	O
.	O

Discussion	O

In	O
this	O
study	O
,	O
we	O
identified	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
as	O
novel	O
markers	O
of	O
cells	O
that	O
are	O
more	O
frequently	O
infected	O
in	O
HIV	B-OG
-	O
infected	O
individuals	O
receiving	O
suppressive	O
ART	O
.	O

Co	O
-	O
expression	O
of	O
the	O
3	O
ICs	B-GP
identified	O
a	O
unique	O
subset	O
of	O
CD4	B-GP
+	O
T	O
cells	O
that	O
was	O
strongly	O
associated	O
with	O
the	O
size	O
of	O
the	O
HIV	B-OG
reservoir	O
and	O
that	O
was	O
highly	O
enriched	O
for	O
integrated	O
HIV	B-OG
DNA	O
.	O

Finally	O
,	O
our	O
results	O
provide	O
evidence	O
that	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
at	O
least	O
one	O
of	O
these	O
markers	O
are	O
the	O
major	O
contributors	O
to	O
the	O
pool	O
of	O
inducible	O
HIV	B-OG
genomes	O
during	O
ART	O
.	O

The	O
frequencies	O
of	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
,	O
CTLA	B-GP
-	I-GP
4	I-GP
,	O
LAG	B-GP
-	I-GP
3	I-GP
and	O
TIM	B-GP
-	I-GP
3	I-GP
were	O
similar	O
to	O
those	O
reported	O
by	O
other	O
groups	O
[	O
41	O
–	O
44	O
],	O
indicating	O
that	O
the	O
cohort	O
of	O
participants	O
used	O
for	O
this	O
study	O
is	O
likely	O
to	O
be	O
representative	O
of	O
the	O
HIV	B-OG
population	O
receiving	O
suppressive	O
ART	O
.	O

In	O
addition	O
,	O
the	O
association	O
between	O
PD	B-GP
-	I-GP
1	I-GP
and	O
TIGIT	B-GP
expression	O
on	O
CD4	B-GP
+	O
T	O
cells	O
and	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
carrying	O
HIV	B-OG
proviruses	B-OG
was	O
in	O
agreement	O
with	O
previously	O
reported	O
findings	O
[	O
6	O
,	O
24	O
,	O
41	O
].	O

We	O
found	O
positive	O
associations	O
between	O
the	O
expression	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
LAG	B-GP
-	I-GP
3	I-GP
and	O
TIGIT	B-GP
in	O
CD4	B-GP
+	O
T	O
cells	O
and	O
the	O
frequency	O
of	O
cells	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
.	O

Of	O
note	O
,	O
these	O
three	O
markers	O
showed	O
the	O
strongest	O
inverse	O
associations	O
with	O
CD4	B-GP
+	O
T	O
cell	O
counts	O
among	O
the	O
7	O
markers	O
we	O
examined	O
,	O
suggesting	O
a	O
link	O
between	O
T	O
cell	O
homeostasis	O
and	O
HIV	B-OG
persistence	O
(	O
S4A	O
,	O
S4B	O
and	O
S4C	O
Fig	O
).	O

The	O
associations	O
between	O
individual	O
IC	O
expression	O
and	O
HIV	B-OG
persistence	O
marker	O
were	O
substantially	O
smaller	O
and	O
no	O
longer	O
statistically	O
significant	O
after	O
adjusting	O
for	O
current	O
CD4	B-GP
+	O
T	O
-	O
cell	O
count	O
.	O

These	O
findings	O
from	O
the	O
negative	O
binomial	O
regression	O
models	O
suggest	O
that	O
the	O
current	O
CD4	B-GP
+	O
T	O
-	O
cell	O
count	O
is	O
an	O
important	O
predictor	O
of	O
the	O
size	O
of	O
the	O
HIV	B-OG
reservoir	O
when	O
measured	O
as	O
the	O
frequency	O
of	O
cells	O
harboring	O
proviral	O
genomes	O
[	O
6	O
,	O
37	O
].	O

Importantly	O
,	O
and	O
in	O
contrast	O
to	O
cells	O
expressing	O
a	O
single	O
marker	O
,	O
the	O
frequency	O
of	O
cells	O
co	O
-	O
expressing	O
simultaneously	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
was	O
strongly	O
associated	O
with	O
the	O
size	O
of	O
the	O
reservoir	O
and	O
remained	O
after	O
adjusting	O
for	O
nadir	O
and	O
current	O
CD4	B-GP
+	O
T	O
-	O
cell	O
counts	O
.	O

This	O
result	O
reinforces	O
the	O
possibility	O
of	O
a	O
direct	O
—	O
and	O
maybe	O
synergistic	O
—	O
role	O
for	O
these	O
molecules	O
in	O
HIV	B-OG
persistence	O
during	O
ART	O
.	O

In	O
addition	O
,	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
co	O
-	O
expressing	O
simultaneously	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
positively	O
correlated	O
with	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
HLADR	B-GP
/	O
CD38	B-GP
(	O
p	O
=	O
0	O
.	O
003	O
,	O
r	O
=	O
0	O
.	O
42	O
)	O
and	O
Ki67	B-GP
(	O
p	O
=	O
0	O
.	O
022	O
,	O
r	O
=	O
0	O
.	O
33	O
)	O
(	O
S1D	O
and	O
S1E	O
Text	O
and	O
S4D	O
and	O
S4E	O
Fig	O
).	O

These	O
associations	O
suggest	O
that	O
the	O
persistence	O
of	O
the	O
small	O
pool	O
of	O
cells	O
expressing	O
the	O
3	O
markers	O
is	O
associated	O
with	O
T	O
cell	O
activation	O
and	O
proliferation	O
.	O

Interestingly	O
,	O
we	O
observed	O
a	O
strong	O
negative	O
association	O
between	O
CD160	B-GP
expression	O
and	O
2	O
-	O
LTR	O
circles	O
.	O

Notably	O
,	O
this	O
correlation	O
remained	O
after	O
adjusting	O
for	O
current	O
and	O
nadir	O
CD4	B-GP
+	O
T	O
cell	O
counts	O
.	O

A	O
possible	O
explanation	O
for	O
these	O
findings	O
is	O
that	O
CD160	B-GP
+	O
cells	O
may	O
be	O
preferential	O
targets	O
for	O
infection	B-DS
and	O
depletion	O
during	O
ART	O
,	O
which	O
would	O
explain	O
the	O
strong	O
negative	O
association	O
between	O
the	O
frequency	O
of	O
CD160	B-GP
+	O
CD4	B-GP
+	O
T	O
cells	O
and	O
a	O
putative	O
marker	O
of	O
persistent	O
viral	O
replication	O
.	O

By	O
sorting	O
TCM	O
,	O
TTM	O
and	O
TEM	O
cells	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
,	O
we	O
observed	O
that	O
cells	O
expressing	O
these	O
markers	O
were	O
enriched	O
for	O
HIV	B-OG
-	O
infected	O
cells	O
in	O
different	O
memory	O
CD4	B-GP
+	O
T	O
-	O
cells	O
subsets	O
during	O
ART	O
.	O

While	O
LAG	B-GP
-	I-GP
3	I-GP
enriched	O
for	O
integrated	O
HIV	B-OG
DNA	O
in	O
all	O
memory	O
subsets	O
(	O
TCM	O
,	O
TTM	O
,	O
and	O
TEM	O
),	O
PD	B-GP
-	I-GP
1	I-GP
and	O
TIGIT	B-GP
enriched	O
for	O
HIV	B-OG
genomes	O
exclusively	O
in	O
TTM	O
and	O
TEM	O
cells	O
,	O
respectively	O
.	O

These	O
observations	O
suggest	O
that	O
ICs	B-GP
may	O
exert	O
different	O
pro	O
-	O
latency	O
effects	O
in	O
subsets	O
endowed	O
with	O
distinct	O
proliferative	O
and	O
activation	O
status	O
.	O

One	O
may	O
hypothesize	O
that	O
different	O
ICs	B-GP
provide	O
infected	O
cells	O
with	O
different	O
selective	O
advantage	O
to	O
persist	O
by	O
counteracting	O
distinct	O
stimuli	O
specific	O
to	O
an	O
individual	O
memory	O
cell	O
subset	O
.	O

Further	O
investigations	O
will	O
be	O
needed	O
to	O
characterize	O
the	O
mechanisms	O
by	O
which	O
these	O
ICs	B-GP
may	O
specifically	O
contribute	O
to	O
HIV	B-OG
persistence	O
within	O
these	O
distinct	O
subsets	O
.	O

Overall	O
,	O
the	O
majority	O
of	O
inducible	O
HIV	B-OG
genomes	O
were	O
found	O
in	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
at	O
least	O
one	O
of	O
these	O
markers	O
(	O
median	O
of	O
76	O
%).	O

Although	O
triple	O
negative	O
cells	O
also	O
contain	O
inducible	O
HIV	B-OG
genomes	O
,	O
our	O
data	O
provide	O
evidence	O
that	O
there	O
is	O
an	O
enrichment	O
for	O
inducible	O
viral	O
genomes	O
in	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
these	O
markers	O
.	O

Importantly	O
,	O
we	O
found	O
a	O
gradual	O
enrichment	O
in	O
integrated	O
HIV	B-OG
DNA	O
in	O
cells	O
that	O
express	O
multiple	O
ICs	B-GP
simultaneously	O
.	O

This	O
observation	O
mirrors	O
the	O
synergistic	O
mechanisms	O
of	O
action	O
of	O
these	O
receptors	O
to	O
dampen	O
T	O
cell	O
functions	O
.	O

Indeed	O
,	O
LAG	B-GP
-	I-GP
3	I-GP
and	O
PD	B-GP
-	I-GP
1	I-GP
are	O
commonly	O
co	O
-	O
expressed	O
on	O
exhausted	O
or	O
dysfunctional	O
T	O
cells	O
in	O
models	O
of	O
chronic	B-DS
infections	I-DS
[	O
45	O
],	O
autoimmune	B-DS
diseases	I-DS
[	O
46	O
],	O
and	O
cancers	B-DS
[	O
47	O
,	O
48	O
].	O

Potential	O
synergistic	O
functions	O
were	O
highlighted	O
in	O
murine	O
models	O
of	O
autoimmune	B-DS
diseases	I-DS
[	O
49	O
].	O

Anti	O
-	O
LAG	B-GP
-	I-GP
3	I-GP
blocking	O
mAb	O
has	O
recently	O
entered	O
clinical	O
testing	O
in	O
cancer	B-DS
in	O
monotherapy	O
or	O
in	O
combination	O
therapy	O
with	O
anti	O
-	O
PD	B-GP
-	I-GP
1	I-GP
(	O
NCT01968109	O
).	O

Additionally	O
,	O
TIGIT	B-GP
is	O
co	O
-	O
expressed	O
with	O
PD	B-GP
-	I-GP
1	I-GP
on	O
activated	O
CD8	B-GP
+	O
tumor	B-DS
-	O
infiltrating	O
lymphocytes	O
from	O
patients	O
with	O
melanoma	B-DS
[	O
50	O
].	O

Blockages	O
of	O
TIGIT	B-GP
and	O
PD	B-GP
-	I-GP
1	I-GP
synergize	O
to	O
improve	O
T	O
cell	O
proliferation	O
,	O
cytokines	B-GP
production	O
and	O
degranulation	O
in	O
vivo	O
in	O
melanoma	B-DS
treatment	O
and	O
in	O
vitro	O
in	O
HIV	B-DS
infection	I-DS
[	O
24	O
,	O
50	O
].	O

All	O
together	O
,	O
these	O
studies	O
indicate	O
that	O
ICs	B-GP
can	O
synergize	O
to	O
repress	O
T	O
cell	O
functions	O
and	O
suggest	O
that	O
these	O
synergies	O
may	O
also	O
play	O
a	O
role	O
in	O
HIV	B-OG
persistence	O
during	O
ART	O
.	O

The	O
expression	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
LAG	B-GP
-	I-GP
3	I-GP
and	O
TIM	B-GP
-	I-GP
3	I-GP
on	O
CD4	B-GP
+	O
and	O
CD8	B-GP
+	O
T	O
cells	O
prior	O
to	O
ART	O
was	O
recently	O
identified	O
as	O
a	O
strong	O
predictor	O
of	O
time	O
to	O
viral	O
rebound	O
after	O
treatment	O
interruption	O
in	O
the	O
SPARTAC	O
study	O
[	O
43	O
].	O

It	O
is	O
possible	O
that	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
these	O
markers	O
before	O
ART	O
represent	O
a	O
preferential	O
niche	O
for	O
the	O
establishment	O
of	O
a	O
stable	O
reservoir	O
for	O
HIV	B-OG
and	O
that	O
latently	O
infected	O
cells	O
expressing	O
these	O
markers	O
preferentially	O
persist	O
during	O
ART	O
,	O
as	O
suggested	O
by	O
our	O
observations	O
.	O

In	O
our	O
study	O
,	O
we	O
identified	O
a	O
discrete	O
subset	O
of	O
CD4	B-GP
+	O
T	O
cells	O
co	O
-	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
as	O
an	O
important	O
predictor	O
of	O
the	O
frequency	O
of	O
cells	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
during	O
ART	O
.	O

Of	O
note	O
,	O
the	O
expression	O
of	O
TIGIT	B-GP
before	O
ART	O
initiation	O
was	O
not	O
measured	O
in	O
the	O
SPARTAC	O
study	O
and	O
further	O
studies	O
will	O
be	O
needed	O
to	O
determine	O
if	O
this	O
IC	O
could	O
also	O
represent	O
a	O
pre	O
-	O
ART	O
predictor	O
of	O
viral	O
rebound	O
.	O

Our	O
data	O
provide	O
a	O
rationale	O
for	O
the	O
use	O
of	O
immune	O
checkpoint	O
blockers	O
(	O
ICBs	O
)	O
to	O
target	O
latently	O
infected	O
cells	O
during	O
ART	O
.	O

Targeting	O
ICs	B-GP
by	O
ICBs	O
,	O
a	O
novel	O
class	O
of	O
molecules	O
in	O
development	O
in	O
oncology	O
,	O
may	O
have	O
a	O
double	O
benefit	O
in	O
the	O
context	O
of	O
HIV	B-OG
remission	O
by	O
both	O
targeting	O
latently	O
infected	O
cells	O
and	O
restoring	O
HIV	B-OG
-	O
specific	O
T	O
cell	O
immunity	O
.	O

By	O
enhancing	O
T	O
cell	O
activation	O
and	O
increasing	O
viral	O
transcription	O
,	O
ICBs	O
may	O
facilitate	O
HIV	B-OG
reactivation	O
in	O
latently	O
infected	O
cells	O
when	O
used	O
alone	O
or	O
in	O
combination	O
with	O
latency	O
reversing	O
agents	O
.	O

The	O
anti	O
-	O
CTLA	B-GP
-	I-GP
4	I-GP
antibody	B-GP
iplimumab	O
was	O
recently	O
shown	O
to	O
significantly	O
increase	O
CA	O
-	O
US	O
HIV	B-OG
RNA	O
in	O
an	O
HIV	B-OG
-	O
infected	O
individual	O
on	O
ART	O
,	O
consistent	O
with	O
latency	O
reversal	O
[	O
51	O
].	O

An	O
alternative	O
mechanism	O
of	O
action	O
of	O
some	O
ICBs	O
would	O
be	O
to	O
directly	O
deplete	O
cells	O
expressing	O
these	O
markers	O
,	O
as	O
observed	O
with	O
the	O
anti	O
-	O
CTLA	B-GP
-	I-GP
4	I-GP
ipilumimab	O
,	O
which	O
induces	O
direct	O
elimination	O
of	O
CTLA	B-GP
-	I-GP
4	I-GP
+	O
regulatory	O
T	O
cells	O
in	O
tumor	B-DS
tissue	O
in	O
patients	O
with	O
melanoma	B-DS
[	O
52	O
].	O

Our	O
results	O
suggest	O
that	O
the	O
administration	O
of	O
antibodies	B-GP
with	O
effector	O
functions	O
targeting	O
PD	B-GP
-	I-GP
1	I-GP
,	O
LAG	B-GP
-	I-GP
3	I-GP
and	O
TIGIT	B-GP
may	O
significantly	O
reduce	O
the	O
size	O
of	O
the	O
latent	O
HIV	B-OG
reservoir	O
during	O
ART	O
by	O
targeting	O
cells	O
in	O
which	O
HIV	B-OG
persists	O
.	O

Several	O
limitations	O
are	O
associated	O
with	O
our	O
study	O
.	O

We	O
have	O
not	O
adjusted	O
p	O
-	O
values	O
for	O
multiple	O
comparisons	O
,	O
because	O
such	O
adjustment	O
would	O
neglect	O
the	O
biological	O
relationships	O
among	O
our	O
positive	O
results	O
and	O
would	O
require	O
that	O
each	O
analysis	O
detract	O
from	O
the	O
others	O
,	O
rather	O
than	O
reinforcing	O
one	O
another	O
when	O
there	O
is	O
biological	O
coherence	O
[	O
53	O
]	O
(	O
S1F	O
Text	O
).	O

Nevertheless	O
,	O
our	O
evidence	O
may	O
be	O
weaker	O
than	O
if	O
it	O
had	O
arisen	O
from	O
a	O
narrower	O
set	O
of	O
analyses	O
,	O
and	O
,	O
in	O
any	O
case	O
,	O
additional	O
studies	O
will	O
be	O
needed	O
to	O
confirm	O
the	O
hypotheses	O
supported	O
by	O
our	O
results	O
.	O

Most	O
of	O
our	O
analyses	O
were	O
performed	O
using	O
integrated	O
HIV	B-OG
DNA	O
as	O
a	O
marker	O
of	O
HIV	B-OG
persistence	O
.	O

We	O
chose	O
this	O
readout	O
as	O
it	O
was	O
applicable	O
to	O
small	O
subsets	O
of	O
CD4	B-GP
+	O
T	O
cells	O
on	O
which	O
measures	O
of	O
replication	O
competent	O
HIV	B-OG
cannot	O
be	O
performed	O
.	O

The	O
majority	O
of	O
viral	O
genomes	O
persisting	O
during	O
ART	O
are	O
known	O
to	O
be	O
defective	O
[	O
40	O
,	O
54	O
],	O
and	O
although	O
our	O
experiments	O
indicate	O
that	O
cells	O
that	O
express	O
ICs	B-GP
can	O
produce	O
multiply	O
spliced	O
RNA	O
upon	O
activation	O
(	O
TILDA	O
),	O
they	O
do	O
not	O
demonstrate	O
that	O
replication	O
competent	O
virus	B-OG
persists	O
in	O
these	O
cells	O
.	O

In	O
addition	O
,	O
our	O
results	O
are	O
limited	O
to	O
circulating	O
T	O
cells	O
.	O

It	O
is	O
possible	O
and	O
indeed	O
likely	O
that	O
the	O
biology	O
of	O
ICs	B-GP
expression	O
and	O
HIV	B-OG
persistence	O
will	O
differ	O
in	O
tissues	O
,	O
particularly	O
in	O
secondary	O
lymphoid	O
tissues	O
where	O
many	O
of	O
the	O
ligands	O
for	O
these	O
receptors	O
are	O
likely	O
to	O
be	O
expressed	O
.	O

A	O
better	O
understanding	O
of	O
the	O
nature	O
of	O
the	O
cells	O
that	O
encompass	O
the	O
latent	O
HIV	B-OG
reservoir	O
is	O
a	O
prerequisite	O
to	O
the	O
development	O
of	O
novel	O
curative	O
strategies	O
.	O

Despite	O
similarities	O
in	O
their	O
mechanisms	O
of	O
action	O
,	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
are	O
likely	O
to	O
be	O
non	O
-	O
redundant	O
in	O
their	O
functions	O
.	O

Blocking	O
these	O
pathways	O
simultaneously	O
may	O
show	O
synergies	O
in	O
latency	O
reversal	O
,	O
as	O
suggested	O
by	O
their	O
synergistic	O
activities	O
in	O
the	O
restoration	O
of	O
T	O
cell	O
immunity	O
.	O

Supporting	O
Information	O

Materials	O
&	O
Methods	O
supporting	O
information	O
.	O

(	O
DOCX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Gating	O
strategy	O
of	O
7	O
ICs	B-GP
on	O
CD4	B-GP
+	O
T	O
cells	O
.	O

Expression	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
CTLA	B-GP
-	I-GP
4	I-GP
,	O
LAG	B-GP
-	I-GP
3	I-GP
,	O
TIGIT	B-GP
,	O
TIM	B-GP
-	I-GP
3	I-GP
,	O
CD160	B-GP
and	O
2B4	B-GP
on	O
CD4	B-GP
+	O
T	O
cells	O
in	O
individuals	O
receiving	O
suppressive	O
ART	O
(	O
n	O
=	O
48	O
).	O

Representative	O
dot	O
plots	O
from	O
one	O
participant	O
.	O

(	O
EPS	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Contribution	O
of	O
ICs	B-GP
expressing	O
cells	O
to	O
the	O
HIV	B-OG
reservoir	O
pool	O
.	O

The	O
contribution	O
of	O
cells	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
(	O
A	O
),	O
TIGIT	B-GP
(	O
B	O
)	O
or	O
LAG	B-GP
-	I-GP
3	I-GP
(	O
C	O
)	O
to	O
the	O
total	O
HIV	B-OG
reservoir	O
by	O
taking	O
into	O
account	O
the	O
frequency	O
of	O
these	O
subsets	O
within	O
the	O
CD4	B-GP
compartment	O
and	O
their	O
relative	O
infection	B-DS
frequencies	O
(	O
n	O
=	O
12	O
,	O
n	O
=	O
9	O
and	O
n	O
=	O
7	O
,	O
respectively	O
).	O

Horizontal	O
bars	O
indicate	O
median	O
values	O
.	O

(	O
EPS	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Frequency	O
of	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
in	O
PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	B-GP
/	O
LAG	B-GP
-	I-GP
3	I-GP
triple	O
–(	O
LPT	O
-),	O
PD	B-GP
-	I-GP
1	I-GP
single	O
+	O
(	O
P	O
),	O
TIGIT	B-GP
single	O
+	O
(	O
T	O
),	O
LAG	B-GP
-	I-GP
3	I-GP
single	O
+	O
(	O
L	O
),	O
PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	B-GP
double	O
+	O
(	O
PT	O
),	O
TIGIT	B-GP
/	O
LAG	B-GP
-	I-GP
3	I-GP
double	O
+	O
(	O
LT	O
),	O
PD	B-GP
-	I-GP
1	I-GP
/	O
LAG	B-GP
-	I-GP
3	I-GP
double	O
+	O
(	O
LP	O
)	O
and	O
PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	B-GP
/	O
LAG	B-GP
-	I-GP
3	I-GP
triple	O
+	O
(	O
LPT	O
+)	O
cells	O
.	O

Raw	O
data	O
from	O
the	O
5	O
subjects	O
presented	O
in	O
Fig	O
4B	O
.	O

(	O
EPS	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
are	O
associated	O
with	O
markers	O
of	O
activation	O
/	O
proliferation	O
.	O

(	O
A	O
),	O
(	O
B	O
),	O
(	O
C	O
)	O
Associations	O
between	O
the	O
current	O
CD4	B-GP
+	O
T	O
cell	O
counts	O
and	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
,	O
respectively	O
.	O

P	O
,	O
r	O
values	O
were	O
obtained	O
from	O
Spearman	O
’	O
s	O
ranked	O
analysis	O
.	O

(	O
D	O
),	O
(	O
E	O
)	O
Associations	O
between	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
co	O
-	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
and	O
the	O
frequencies	O
of	O
CD4	B-GP
+	O
T	O
cells	O
expression	O
HLA	B-GP
-	I-GP
DR	I-GP
/	O
CD38	B-GP
and	O
Ki67	B-GP
respectively	O
.	O

P	O
,	O
r	O
values	O
were	O
obtained	O
from	O
Spearman	O
’	O
s	O
ranked	O
analysis	O
.	O

(	O
EPS	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Virological	O
markers	O
of	O
HIV	B-OG
persistence	O
.	O

(	O
DOCX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Negative	O
binomial	O
regression	O
models	O
to	O
assess	O
the	O
relationship	O
between	O
Total	O
HIV	B-OG
DNA	O
and	O
Immune	O
Checkpoints	O
expression	O
on	O
CD4	B-GP
+	O
T	O
cells	O
.	O

(	O
DOCX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Negative	O
binomial	O
regression	O
models	O
to	O
assess	O
the	O
relationship	O
between	O
2	O
-	O
LTR	O
circles	O
and	O
Immune	O
Checkpoints	O
expression	O
on	O
CD4	B-GP
+	O
T	O
cells	O
.	O

(	O
DOCX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Negative	O
binomial	O
regression	O
models	O
to	O
assess	O
the	O
relationship	O
between	O
cell	O
-	O
associated	O
US	O
HIV	B-OG
RNA	O
and	O
Immune	O
Checkpoints	O
expression	O
on	O
CD4	B-GP
+	O
T	O
cells	O
.	O

(	O
DOCX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Negative	O
binomial	O
regression	O
models	O
to	O
compare	O
integrated	O
HIV	B-OG
DNA	O
in	O
cells	O
expressing	O
the	O
Immune	B-GP
Checkpoint	I-GP
Molecule	I-GP
with	O
integrated	O
HIV	B-OG
DNA	O
in	O
cells	O
not	O
expressing	O
the	O
Immune	B-GP
Checkpoint	I-GP
Molecule	I-GP
.	O

(	O
DOCX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Frequencies	O
of	O
ICs	B-GP
on	O
CD4	B-GP
+	O
T	O
cells	O
in	O
cohort	O
1	O
(	O
n	O
=	O
48	O
).	O

(	O
DOCX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

